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Chapter 1
General introduction
Shiromani Janki
Department of Surgery, Erasmus MC University Medical Center, Rotterdam, The Netherlands 
Adapted from:  
Surgical aspects of live kidney donation - An updated review Frontiers of Bioscience (Elite Edition). 2015 
Jan 1;7:346-65
Long-term follow-up after live kidney donation (LOVE) study: a longitudinal comparison study protocol 
BMC Nephrology 2016 Feb 1;17(1):14
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The kidneys are two bean shaped organs, each about 10cm in length, located under 
the diaphragm at the rear of the abdominal cavity in the retroperitoneal space behind 
the intestines. Blood supply is received from direct branches of the abdominal aorta, 
the left and right renal artery and after fi ltration the blood drains into the left and renal 
vein respectively, which connect with the inferior vena cava. Each kidney contains up to 
a million functioning units called nephrons (Figure 1). A nephron consists of a fi ltering 
unit of tiny blood vessels called a glomerulus attached to tubules. When blood enters 
the glomerulus, it is fi ltered and the remaining fl uid then passes along the tubules. In 
the tubules, chemicals and water are either added to or removed from this fi ltered fl uid 
according to the body’s need, the fi nal product is the urine we excrete. The kidney is 
an essential organ, which plays a pivotal role in acid/base balance, sodium/potassium 
balance, calcium metabolism, regulation of blood pressure, red blood cell synthesis, and 
excretion of metabolites.
Figure 1. Kidney and nephron
A progressive loss in kidney function could ultimately lead to end-stage renal disease 
(ESRD), where kidneys are no longer able to remove waste and excess water from the 
body and patients require renal replacement therapy to survive. Renal replacement 
therapy may consist of maintenance dialysis or renal transplantation. Renal transplanta-
tion off ers a better prognosis and long-term benefi t to patients with ESRD compared 
with other renal replacement therapies1.
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In the early 1950s, Rene Kuss and Joseph Murray performed the first successful kidney 
transplantations using identical twins as live donors in France and the United States, 
respectively2,3. The invention of adequate immunosuppressive therapy in the 1960s 
enabled deceased donor kidney transplantation, preventing risky operations performed 
on healthy individuals. As enough deceased donors were present at that time, live kid-
ney donor transplantation was pushed into the background. In the late 1980s and 1990s, 
a discrepancy between deceased organ demand and supply occurred due to an increas-
ing number of patients suffering from ESRD and a stagnating number of transplants. This 
prompted renewed interest in live donor kidney transplantation as an alternative. With 
the increase in the number of live kidney donor transplantations significant benefits 
over kidney transplantation from a deceased donor were demonstrated: superior organ 
quality, increased graft survival and the possibility of pre-emptive transplantation1. 
Live kidney donation has been proven to be a safe surgical procedure4-7 with a very 
low mortality rate8,9. Justified by all these excellent results a significant increase in live 
kidney donations was observed. Thus, live donor kidney transplantation has helped to 
narrow the gap between deceased organ shortage and the number of ESRD patients on 
the transplant waiting list10. Nevertheless, a shortage in donor kidneys still remains, and 
against this background an extension of the donor acceptance criteria was observed 
in recent years; donors with comorbidities such as cardiovascular disease, obesity and 
higher age are no longer denied for donation11,12. As a result, nearly 30,000 transplants 
from live kidney donors are annually performed worldwide, and this number has re-
mained stable over the past decade13,14.
With the extension of donor acceptance criteria we must be attentive to the potential 
effect on the donor’s health, as any harm to the donor has to be prevented. Live kidney 
donation is possible because of the capacity of the remnant kidney to physiologically 
compensate for the decrease in kidney function by hyperfiltration and increase in kidney 
volume15-21. Increase in volume of the remnant kidney can be considered as the physi-
ological response to adapt for the decrease in kidney function. To assess which individu-
als are suitable for live kidney donation potential donors are exhaustively screened by a 
multidisciplinary team of nephrologists, transplant surgeons and anesthesiologists prior 
to donation. Medical suitability of the donor is assessed by using criteria defined by the 
Amsterdam Forum, a group of experts that developed an international standard of care 
on live donor evaluation in 2004. They set forth a list of all the (relative) contra-indica-
tions to live kidney donation. Donors must have sufficient renal function (GFR more than 
80 ml/min), no hypertension (less than 140/90), no obesity (BMI less than 35 kg/m²), 
negative urine analysis for protein (less than 300mg/24 hours), no diabetes, no kidney 
stone disease, no malignancy or recurrent urinary tract infections, no or at most a minor 
cardiovascular or pulmonary risk, no smoking, and no alcohol22. In addition to providing 
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detailed information on the donor’s medical history, imaging is of utmost importance in 
selecting donors. The decision which kidney can safely be donated is largely dependent 
on imaging results. The guiding principle for this choice is that the donor should remain 
with the “best“ kidney, i.e. the kidney with the lowest long-term risk for the donor. This 
requires diagnostic imaging by CT or MRI to determine kidney size, vascular anatomy, 
ureter anatomy, renal cysts or other abnormalities in both kidneys. If there is a significant 
mismatch in size a renal split function using excretion scintigraphy is indicated.
Live kidney donors are individuals who willingly undergo major surgery to improve the 
well-being of someone else. Over the years, the discomfort of the operation has been re-
duced significantly by using minimal invasive procedures resulting in an excellent qual-
ity of life after donation. In the past, all live donor kidneys were procured by a 15 to 25 
cm flank incision with transection of all abdominal wall muscles23. This procedure mark-
edly injured the abdominal wall, resulting in significant postoperative pain, an average 
hospital stay of one week and prolonged recovery time. Fortunately, renewed interest in 
live kidney donation occurred in an era in which minimally invasive surgery was gradu-
ally replacing conventional surgery. In 1995, Ratner and colleagues performed the first 
laparoscopic donor nephrectomy24. Various alternatives to the laparoscopic approach 
have been presented since, including hand-assisted laparoscopic donor nephrectomy4,5, 
retroperitoneoscopic donor nephrectomy, robot-assisted donor nephrectomy7, laparo-
endoscopic single-site and natural orifice transluminal endoscopic donor nephrectomy. 
Laparoscopic donor nephrectomy is now considered the gold standard25.
Studies on short-term follow-up show excellent results regarding kidney function, 
mortality and morbidity8,26-28. It is pivotal to minimize risks and maximize donor safety 
on short as well as long-term. Three renowned research groups in the field of living 
kidney donation recently reported unfavourable long-term outcomes for live kidney 
donors following donation compared to non-donors, including an increased risk for 
cardiovascular and overall mortality29, increased risk for ESRD29,30, and increased risk for 
gestational hypertension and preeclampsia31. However, it should be stressed that the 
number of events and absolute risks are low, but with the inclusion of more extended 
donor acceptance criteria the observation may be very relevant. Previous publications 
from these research groups did not demonstrate unfavourable outcomes detrimental to 
live kidney donors, as they reported a lower risk of long-term cardiovascular32 and overall 
mortality28,32,33 and lower risk of cardiovascular events33. To uncover these contradictory 
results, the study design and analysis of the three most recent studies and the previous 
studies from the same research groups were compared in Chapter 2.
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In 2015, the 1500th live donor kidney transplantation was performed at the Erasmus MC, 
University Medical Center, Rotterdam, The Netherlands. With the availability of large 
prospective databases of these donors we have the unique opportunity to study long-
term outcome. This donor population consists of prospective cohorts included in three 
randomized controlled trials on surgical techniques between 2001-2004, 2008-2010, 
and 2011-20124-6. One hundred donors of the first cohort were included in a randomized 
controlled trial between 2001 and 2004 in which mini-incision open donor nephrectomy 
and laparoscopic donor nephrectomy were compared. Laparoscopic donor nephrec-
tomy resulted in faster recovery, less fatigue and a better quality of life compared with 
mini-incision open donor nephrectomy up to one year after the donation. However, the 
procedures were equal safe with no difference in graft function6. The difference in fatigue 
and quality of life scores one year after donation warranted longer follow-up and physi-
cal and psychosocial outcomes were analysed 3 to 5 years after donor nephrectomy. The 
results of this study demonstrated no difference between mini-incision open donor 
nephrectomy and laparoscopic donor nephrectomy in kidney function, quality of life, 
and mortality34. However, the occurrence of, for example, cardiovascular diseases take 
years to emerge. With donors being a group of selected healthy individuals, it is highly 
likely that this will be missed during a short-term follow-up of less than ten years. Recent 
studies demonstrated an increased risk for ESRD29,30 and mortality29 compared to non-
donors. Therefore, evidence on long-term outcome is essential. In Chapter 3 we present 
the ten-year follow-up of our previous conducted randomized controlled trial compar-
ing mini-incision open donor nephrectomy and laparoscopic donor nephrectomy.
Driven by its success the acceptance criteria of the living donation program have been 
extended in the past decade and older donors and donors with minor comorbidities 
such as hypertension and obesity have become eligible for live kidney donation14,35-37. 
Previous donation outcome studies report on cohorts including low numbers of donors 
with minor comorbidities. Therefore, these studies do not apply for donors under the 
current donor acceptance criteria. The second prospective cohort of 190 live kidney 
donors were included in a randomized controlled trial between 2008 and 2010 in which 
left-sided laparoscopic donor nephrectomy and hand-assisted donor nephrectomy were 
compared. This period represents the extension of the living kidney donor acceptance 
criteria. In Chapter 4 we present the five-year follow-up of this previous prospective co-
hort, including live kidney donors who donated with pre-existing minor comorbidities.
The aforementioned two chapters study a selection of the entire Erasmus MC donor 
population and do not include a matched comparison cohort of non-donors. Studies on 
long-term outcomes should uncover risk estimates for potential donors and how these 
risks would change if an individual becomes a live kidney donor. Therefore, comparison 
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studies with non-donors are important to uncover potential risks additional to donation. 
Till date there are nine studies in which long-term outcomes are compared between do-
nors and selected non-donors with an average follow-up of ten or more years29,31-33,38-42. 
These studies on long-term follow-up of live kidney donors compared with non-donors 
demonstrate that the morbidity and mortality increases with the duration of follow-up 
and subsequent aging. However, these long-term studies have contradictory outcomes 
regarding kidney function, incidence of hypertension, ESRD and mortality detriment to 
donors. These inconsistencies represent the differences in the methodology of these 
studies questioning the comparability of donors and the selected non-donors. Live kid-
ney donors are exhaustively screened prior to donation, resulting in a population that is 
inherently healthier than the general population. Therefore, selecting non-donors with 
health similar to accepted donors is difficult and may affect estimates of any potential 
risks additional to donation. Furthermore, the occurrence of some comorbidities takes 
years to emerge and might be missed during a short-term follow-up. Thus, in addition to 
the problem of adequate selection, an extended follow-up period for live kidney donors 
is important to demonstrate the risks of donation on long-term health29,30. Therefore, 
high quality research is needed.
To increase the sample size of our previous studies and taking in consideration the 
strengths and limitations of the current literature we designed a comparative follow-up 
study with individual level patient data that comprises the entire Erasmus MC donor 
population from 1981 through 2010. Donors are compared with non-donors derived 
from population-based cohort studies. The aim of this study is to evaluate long-term 
effects after live kidney donation for the donor regarding kidney function, kidney size 
(Chapter 5), the incidence of hypertension, the incidence of diabetes mellitus, the 
incidence of cardiovascular events, cardiovascular and overall mortality, and quality of 
life when compared to non-donors. The preliminary results of this study are presented 
in Chapter 6. Determining the long-term impact of living donation is an essential part 
of evaluating the current donor eligibility criteria and further developing and expanding 
the live kidney donation program.
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ABSTRACT
Live kidney donors are exhaustively screened pre-donation, creating a cohort inher-
ently healthier at baseline than the general population. In recent years, three renowned 
research groups reported unfavourable outcomes for live kidney donors post-donation 
that contradicted their previous studies. Here, we compared the study design and 
analysis of the most recent and previous studies to determine whether the different 
outcomes were due to methodological design or reflect a real potential disadvantage 
for living kidney donors. All six studies on long-term risk after live kidney donation were 
thoroughly screened for the selection of study population, controls, data quality, and 
statistical analysis. Our detailed review of the methodology revealed key differences 
with respect to selection of donors and compared non-donors, data quality, follow-up 
duration, and statistical analysis. In all studies, the comparison group of non-donors was 
healthier than the donors due to more extensive exclusion criteria for non-donors. Five 
of the studies used both restriction and matching to address potential confounding. 
Different matching strategies and statistical analyses were used in the more recent stud-
ies compared to previous studies and follow-up was longer. Recently published papers 
still face bias. Strong points compared to initial analyses are the extended follow-up 
time, large sample sizes and better analysis, hence increasing the reliability to estimate 
potential risks for living kidney donors on the long-term. Future studies should focus 
on equal selection criteria for donors and non-donors, and in the analysis, follow-up 
duration, matched sets, and low absolute risks among donors should be accounted for 
when choosing the statistical technique.
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INTRODUCTION
Live donor kidney transplantation is the treatment of choice for patients with end-stage 
renal disease (ESRD). The benefits of this treatment include pre-emptive transplantation, 
superior organ quality, and increased graft survival1 and have led to an increase in live 
kidney donations and consecutive transplants. Despite this increase, the growing de-
mand for donor kidneys cannot be matched, which has led to an increase in the number 
of extended-criteria live donors with minor comorbidities, such as well-regulated hyper-
tension or higher body mass index (BMI)2. As a result, more than 20,000 transplants from 
live kidney donors are performed annually worldwide, and this number has remained 
stable over the past decade3,4.
Live kidney donors are individuals who willingly undergo major surgery to improve the 
well-being of someone else. It is of the utmost importance to minimize risks, such as the 
intra-operative risk of bleeding5,6 and mortality7, and maximize donor safety during and 
after donation as well as in the long-term. Live kidney donors are exhaustively screened 
by a multidisciplinary team of transplant professionals and anaesthesiologists prior to 
donation, resulting in a cohort that is inherently healthier at baseline than the general 
population. Therefore, selecting non-donors with baseline health similar to accepted 
donors is difficult and may affect estimates of any potential risks additional to donation. 
In addition to the problem of adequate selection, an extended follow-up period for 
live kidney donors is important for revealing the risks of donation on their long-term 
health8,9.
Three renowned research groups recently uncovered unfavourable outcomes for live 
kidney donors following donation compared to non-donors, including an increased risk 
of cardiovascular and overall mortality8, increased risk of ESRD8,9, and increased risk of 
gestational hypertension and preeclampsia10. The number of events and absolute risks 
are low. Previous publications from these research groups Oslo University Hospital, 
Johns Hopkins Medical Institutions, and the Donor Nephrectomy Outcomes Research 
(DONOR) Network did not demonstrate unfavourable outcomes detrimental to live 
kidney donors, as they reported a lower risk of long-term cardiovascular11 and overall 
mortality11–13 and lower risk of cardiovascular events13. This is remarkable because 
studies from the same research group largely included the same donor population. We 
compared the study design and analysis of the three most recent studies and the previ-
ous studies from the same research groups.
20 Chapter 2
MATERIALS AND METHODS
Literature search
We searched for studies that reported negative outcomes following live kidney dona-
tion using MEDLINE, Embase, CENTRAL (the Cochrane Library 2013), OvidSP, and Google 
Scholar.
Literature screening
We selected studies published in the last 5 years with an impact factor >15 or high cita-
tion rate >20. We found three studies by three different research groups8–10. Previously, 
studies from these research groups reported favourable outcomes following live kidney 
donation11–13 in the same donor cohort. The discrepancies in outcomes of these studies 
have been highly debated within the transplant community.
Outcome
In light of the impact of these studies on the transplant community, we compared the 
methodology used in the studies and the likely impact on outcomes. The six studies 
were thoroughly screened by two authors (SJ and JNMI) in regard to the selection of the 
study population, data quality, and statistical analysis.
RESULTS
Outcome and selection of study population
The Norwegian studies by Mjoen et al. were published in 201211 and 20148 and report 
on a single centre experience with contradictory results (Table 1). They studied a 
consecutive cohort of 2269 donors who donated between 1963 and 2007 at a single 
centre in Oslo, Norway, where all kidney transplantations in Norway are performed. 
However, there were important differences in the selection and comparability of donors 
and non-donors (Tables 2, 3). In the 2014 study, 368 donors were excluded based on 
antihypertensive medication, blood pressure >140/90 mmHg, BMI >30 kg/m2, age >70 
years or <20 years, macroalbuminuria, or eGFR <70 ml/min per 1.73 m2. This selection 
left only the healthiest donors. In the 2012 study, comparison data on non-donors were 
obtained from the Norwegian background population as provided by Statistics Norway. 
The 2014 study derived the comparison group from a Norwegian population-based co-
hort study (Helseundersøkelsene i Nord-Trøndelag, HUNT 1) carried out between 1984 
and 198714. However, data on kidney function was not available for non-donors, while 
donors with low renal function were excluded from the analysis. Though similar donor 
and non-donor groups were studied, the other two research groups from the US and 
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Canada reported on different outcomes, including long-term mortality12, ESRD9, death 
and major cardiovascular events13, and gestational hypertension and preeclampsia10. 
The previous US analysis selected a donor cohort from the mandated national Organ 
Procurement and Transplantation Network (OPTN) registry. A total of 80,347 donors 
between 1994 and 2009 with a median follow-up of 6.3 years (maximum 12 years) were 
included in this study, excluding 36 donors for whom age was not recorded or were <18 
years old. For the more recent US analysis the selection period was extended to 2011, 
increasing the donor cohort by 15,870 donors to a total of 96,217 donors with a median 
follow-up of 7.6 years (maximum 15 years). Both studies derived their comparison group 
of non-donors from National Health and Nutrition Examination Survey (NHANES) III 
participants12. NHANES participants were matched 1:1 to live donors with replacement 
to a predetermined maximum permissible radius. If information on the live donor’s BMI 
or systolic blood pressure was not available, a match was selected with healthy BMI 
(20–30 kg/m2) or systolic blood pressure (100–140 mmHg). Sampling with replacement 
was performed when a matched participant was the only fit despite ideal and radius 
matching. In the 2012 Canadian analysis, a donor cohort was selected from live kidney 
donors who donated between 1992 and 2009 in Ontario, Canada, and were permanent 
residents of Ontario13. The 2015 study included female live kidney donors who donated 
a kidney between July 1, 1992, and April 30, 2010, and who had at least one pregnancy 
Table 1. Results of studies comparing live kidney donors to non-donors
Study Year Average 
follow-
up, years
Outcome Risk for 
donor
Overall results, donors 
versus non-donors
p-value
Mjoen et al.11 2012 14.7 Overall mortality
Cardiovascular mortality
↓
↓
-
-
<0.001
0.004
Mjoen et al.8 2014 15.1 All cause death
Cardiovascular death
End-stage renal disease
↑
↑
↑
HR 1.30 (95% CI 1.11-1.52)
HR 1.40 (95% CI 1.03-1.91)
302 cases per million; HR 
11.38 (95% CI 4.37-29.6)
0.001
0.030
0.001
Segev et al.12 2010 6.3 Long-term mortality ↓ 1.5% versus 2.9% 0.001
Muzaale et 
al.9
2014 7.6 End-stage renal disease ↑ 30.8 per 10,000 
(95% CI 24.3-38.5) versus 3.9 
per 10,000 (95% CI 0.8-8.9)
0.001
Garg et al.13 2012 6.8 Death or major 
cardiovascular event
Major cardiovascular 
event
↓
↓
2.8 versus 4.1 events per 
1000 person years; HR 0.66 
(95% CI 0.48-0.90)
1.7 versus 2.0 events per 
1000 person years; HR 0.85 
(95% CI 0.57-1.27)
0.010
-
Garg et al.10 2015 11.0 Gestational hypertension 
and preeclampsia
↑ 11% versus 5%; OR 2.4 
(95% CI 1.2-5.0)
0.010
HR, hazard ratio; CI, confidence interval; OR, odds ratio
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with a gestation of at least 20 weeks during follow-up. The study population comprised 
only 88 donors. The non-donor comparison group for both studies was derived from the 
adult general population of Ontario in the Ontario Registered Persons Database, which 
contains demographic and vital status information for all Ontario residents. The starting 
date for follow-up was the date of nephrectomy and assigned as the index date. The 
donor index dates were randomly assigned to all adult residents of Ontario. Residents 
were excluded if any medical conditions that could preclude donation were known. For 
the 2015 study, in addition to previous restrictions depicted in Table 3, women with a 
previous diagnosis of gestational hypertension or preeclampsia were excluded from the 
analysis. Furthermore, the index data was extended to ±2 years to account for era ef-
fects. Each non-donor could be selected only once, resulting in 380,955 potential female 
non-donors (52 % of the original sample), though matched sets could be found for only 
85 donors.
Data quality
Data for donors and non-donors were collected from pre-existing registries or databases 
(Table 2). Data were collected prospectively in national registries for live kidney donors 
in Norway, the US, and Ontario. In addition, the Canadian studies verified the donor 
data from Ontario’s central organ and tissue donation agency, the Trillium Gift of Life, 
with donor medical records from five major transplant centres. The Canadian studies did 
not state if there was any discrepancy between the donor registry and medical records. 
The outcomes were derived from registries in all six studies (Table 2). The Norwegian 
and Canadian studies, as well as the first US study in 2010, linked both the donor and 
non-donor data with the registries containing their studied outcomes. All outcomes 
were specifically coded within the registries. The recent US study in 2014 identified the 
outcome of ESRD differently for donors and non-donors, potentially leading to informa-
tion bias. ESRD was defined as the initiation of maintenance dialysis, receipt of a living 
or deceased donor kidney transplant, or placement on the deceased waiting list. The 
outcome was ascertained by linkage to medical evidence Form 2728 for the Centers 
for Medicare and Medicaid Services (CMS). Donors were also linked to the transplant 
network’s kidney waiting list.
Statistical analysis
All studies used both restriction and matching to address potential confounding except 
for the 2012 analysis by Mjoen et al.11 (Table 3). The Norwegian research group added 
restriction and altered their matching method for their 2014 study. Mjoen et al. used 
Kaplan–Meier analysis without adjustment of confounders in 2012. In 2014, Mjoen et 
al.8, reported 31 ESRD events in 9 donors and 22 in non-donors. A majority of the donors 
who developed ESRD were immediate family members of the recipient. The Cox regres-
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sion analyses for all outcomes including ESRD were adjusted for six confounders: age, 
gender, year of inclusion, blood pressure, BMI, and smoking. A second adjusted model 
was created after multiple imputation of blood pressure, BMI, and smoking. This latter 
model was used for the primary analyses. In contrast, the US and Canadian research 
groups did not alter the restriction and matching methods for their recent analyses. 
Although all outcomes were reported differently, as percentages, hazard ratios, or odds 
ratios depending on the statistical methods used. The US research group performed a 
Kaplan–Meier analysis in both studies but used a bootstrap method to properly esti-
mate the variance of repeated sampling of nondonors in their most recent study9. The 
crude incidence of ESRD was 9 out of 1901 donors and 17 out of 32,621 non-donors, 
resulting in 36 cases of ESRD in the nondonor group after matching with replacement. 
Persons aged ≥65 years, African Americans, and Mexican Americans had an increased 
risk of ESRD, whereas Caucasian non-donors had no risk of ESRD. In the 2012 study by 
the Canadian research group13, differences in baseline characteristics between donors 
and non-donors were assessed using standardized differences. If these differences were 
>10 % they would reflect a meaningful imbalance. A two-sided log-rank test stratified 
on matched sets was used to compare differences in death and cardiovascular outcomes 
between donors and non-donors. Furthermore, a Cox regression stratified on matched 
sets was used to estimate hazard ratios with 95 % confidence intervals. In the 2015 study 
by Garg et al.10, generalized linear models with generalized linear estimating equations 
were used to compare the characteristics of donors and non-donors at the index date, 
and generalized linear mixed models with a random intercept and random effects logis-
tic regression models were used to compare pregnancy characteristics and outcomes. 
These methods account for the correlation structure within matched sets and in women 
with more than one pregnancy during follow-up.
Table 4. Overview of bias in selection of study population, data quality, and statistical analysis
Study
Selection 
bias
Risk of donation
Information 
bias
Risk of donation Confounding Risk of donationD
on
or
s
N
on
-d
on
or
s
D
on
or
s
N
on
-d
on
or
s
Mjoen et al.11 - + Underestimation + - Overestimation - n/a
Mjoen et al.8 + + Overestimation + + Overestimation + Overestimation
Segev et al.12 - + Unclear + + Overestimation - n/a
Muzaale et al.9 - + Overestimation + + Overestimation + Overestimation
Garg et al.13 - + Underestimation + - Overestimation - n/a
Garg et al.10 - + No effect + - Overestimation - n/a
+/-, bias present/not present in study
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DISCUSSION
Our detailed review of the methodology of the different studies on long-term risk after 
live kidney donation revealed key differences with respect to the comparability of 
donors and non-donors in regard to selection, data quality, follow-up, and statistical 
analysis (Table 4).
Selection of the study population
Donors are a pre-screened healthy selection of the population. This is a key issue to 
account for when selecting the comparison group of non-donors. Furthermore, the 
extended donor selection criteria during the past decade2 complicate restriction rules 
when including non-donors. Both Norwegian studies are a good example of choosing 
a more appropriate comparison group when studying the same donor population. 
In the 2012 study by Mjoen et al.11, the full Norwegian background population was 
a comparison group without restriction according to the live kidney donor selection 
criteria. Therefore, the risk attributable to donation could be underestimated despite 
matching 1:3 on age, gender, and year of birth to account for confounding. In their 2014 
study, Mjoen et al.8, used the healthiest donors from the earlier study. In addition, more 
healthy non-donors were derived from a Norwegian population-based cohort study14. 
The restriction rules for donors and non-donors did not entirely lead to a match on renal 
function, cardiovascular disease, and subjective perception of health, leading to the 
possible overestimation of risk detrimental to donors because of healthier non-donors.
The US studies used more extensive restriction rules and matching for NHANES III partici-
pants compared to the healthier donors. NHANES III participants were derived from 81 
counties in the US based on geography and the proportions of minority populations us-
ing probability proportionate to size sampling. Young children, persons aged ≥65 years, 
African Americans, and Mexican Americans were subgroups that were oversampled and 
were not representative of the donor population, the majority of which is Caucasian (75 
%). Both studies used a similar restriction and matching strategy. The entire NHANES 
III cohort comprised 20,024 adult participants. The excluded group (n=10,660) also 
contained participants who would be eligible for living donation, presumably making 
the non-donor group somewhat healthier than the donor population. The 9364 eligible 
NHANES III participants were significantly younger, more educated, had a higher pro-
portion of women and Caucasians, and had a lower proportion of smokers than the 
donor population. This difference may have led to an overestimation of risk attributable 
to donation, which was however not demonstrated in the study by Segev et al.12. The 
2014 study by Mjoen et al. did demonstrate an increased mortality risk for donors. In the 
more recent US study, the strict selection of healthier non-donors made them less likely 
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to develop ESRD. The donor population had significantly higher systolic blood pres-
sure, BMI, and fraction of smokers at baseline, which are all factors associated with an 
increased risk of ESRD15. Thus, the risk attributable to donation was likely overestimated. 
In a recent study by Grams et al.16, a proportion of the same aforementioned US donor 
population consisting of 52,998 live kidney donors was analysed based on their 15-year 
projected risk of ESRD, which was previously reported by Muzaale et al.9. In this recent 
study, the risk of ESRD among live kidney donors was compared to a meta-analysis of 
4,933,314 participants in seven general population cohorts who would be eligible for 
living kidney donation according to 10 demographic and health characteristics. The 
average follow-up for these cohorts was 6.4 years and their 15-year risk projections for 
ESRD were compared among US live kidney donors. The donors had a 3.5–5.3-times 
higher projected 15-year risk than non-donors. As pointed out by Steiner17, the previous 
US study by Muzaale et al.9 reported an 8-times higher incidence of ESRD among donors 
than non-donors. This finding supports the notion that the risk attributable to donation 
was overestimated in that study.
Both Canadian studies used a similar restriction and matching strategy. The extended 
live donor eligibility criteria over the years have caused the broad exclusion criteria to 
encompass participants who would be eligible for living donation, making the non-
donor group healthier. Furthermore, any person who failed to see a physician at least 
once in the 2 years before the index date was not included in the analysis in order to 
ensure that everyone who was included in the analysis had access to health care. This 
restriction could have led to the exclusion of the healthiest non-donors who did not 
require any medical attention in the past years and who would be highly eligible for liv-
ing donation. Nevertheless, this exclusion criterion of healthier non-donors in the Garg 
et al.10 study had no effect on the study results in a sensitivity analysis.
Data quality
The strength of the data collection in all studies was that all data were collected mostly 
from national prospective registries. The Canadian studies even verified donor data with 
the donors’ medical records. However, there were some limitations in the data collection 
in regard to donor and non-donor medical outcomes and missing additional informa-
tion on outcomes. Donors could be more aware of their health than non-donors, leading 
to differential misclassification because all outcomes except for death could have been 
registered earlier. This could have led to more registered outcomes among donors and 
an overestimated risk attributable to donation. Non-donor data from the population-
based studies included data from surveys, giving a subjective rating of HUNT 1 and 
NHANES III participants’ health. These non-donor data were not verified with medical 
records, but were used for restriction, which could have led to an underestimation of risk 
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among non-donors. The 2014 US study prioritized live kidney donors who developed 
ESRD on the deceased donor transplant waiting list18. Pre-emptively placing live kidney 
donors on the deceased waiting list possibly resulted in more registered donors with 
ESRD. This was seen in the higher crude incidence of ESRD among donors (99 out of 
96,217) compared to non-donors (crude incidence 17 out of 9364). Non-donors who 
registered pre-emptively on the deceased waiting list were not identified as having 
ESRD, which caused a delay in the registration of ESRD for non-donors. However, their 
follow-up was longer than that of donors, and most non-donors would either receive 
a transplant or initiate dialysis shortly thereafter. Errors in the estimation of outcomes 
occurred in donors who emigrated; given the large sample sizes in both US studies, this 
is accepted to have had no material effect on the outcomes of the studies. Moreover, it 
will not affect the other studies given the high donor participation.
In the Garg et al. 2012 study, data on blood pressure is lacking19, though previously the 
same authors demonstrated an increase in blood pressure20, which increases the risk 
of cardiovascular events and mortality21. Lely et al.22 pointed out that the severity and 
gestational age at which preeclampsia and gestational hypertension were diagnosed 
was not provided in Garg et al.’s 2015 study. Given that the rate of premature birth was 
not increased, only mild or at-term preeclampsia likely occurred22. Although there is an 
increased risk of preeclampsia and gestational hypertension in donors, the absolute 
risk is low and the severity of the complications, such as premature birth, are less than 
expected from a gynaecological point of view.
Follow-up and statistical analysis
Differences between donors and non-donors in regard to comparability and follow-up 
should be accounted for during the analysis to overcome confounding. Restriction and 
matching is the first step, but matched sets and comparability should also be taken 
into consideration during the analysis. In Mjoen et al.’s 2014 study, the starting date 
of the follow-up for donors occurred decades earlier, causing an increased duration of 
follow-up, as pointed out by Boudville et al.23, leading to a maximum follow-up time of 
43.9 years for donors compared to a maximum of 24.9 years for non-donors. Boudville 
et al. suggested that secular changes in individuals’ health and health care made the 
baseline characteristics not fully comparable between the groups and could have 
resulted in a higher incidence of ESRD among donors. The authors tried to correct for 
this bias by adjusting for year of inclusion. Furthermore, Boudville et al.23 raised some 
concerns about statistical overfitting of the models used. For Cox proportional hazard 
models, a rule of thumb is to have at least 10 events per added confounder24. For the 
outcome ESRD, there were 31 reported events, but the primary analysis adjusted for 
six confounders. Both factors could have led to an overestimated risk attributable to 
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donation. Furthermore, what stands out in the baseline characteristics of the donors 
and non-donors before any matching or adjustments were performed, as pointed out 
by Kaplan et al.25, was the mean age difference of 46.0±11.5 versus 37.6±11.7 years, 
respectively. The higher age of donors could have been a plausible explanation for 
their increased risk of mortality. The Norwegian authors later replied that this difference 
was corrected by using coarsened exact matching in the survival analysis, which cre-
ated strata of the potential confounders:age, gender, year of inclusion, blood pressure, 
BMI, and smoking. Donors and non-donors were matched based on these strata, after 
which the analysis was performed on non-coarsened data. After this matching the mean 
age of donors and non-donors was 46.0 versus 45.7 years, respectively26. For both US 
studies, Matuchansky27 pointed out that a different NHANES cohort should have been 
selected instead of the participants from NHANES III; they proposed that participants in 
the ‘‘continuous NHANES’’ cohort beyond 1994, up to 2006, would have been a better 
chronological fit for their study cohort27. The US authors replied that the strength of 
NHANES III lies in its larger sample size, greater number of geographic areas, and avail-
ability of mortality linkage beyond 10 years. Furthermore, a limitation of ‘‘continuous 
NHANES’’ is that it cannot be used for survival comparisons27, 28. By using their specific 
bootstrap, the authors stated that this technique does not lead to bias, and differences 
in follow-up were accounted for by their use of survival analysis29. As pointed out by Gill 
et al.30, in an editorial accompanying the study by Muzaale et al.9, the crude incidence of 
ESRD was extremely low for NHANES participants: 17 out of 9364. Taken together with 
the longer follow-up of non-donors, replacement of non-donors with long event-free 
survival in matched analysis may have underestimated the risk of ESRD in non-donors30. 
The matching technique was also discussed by Matas et al.15, who stated that matching 
with replacement could magnify any differences between donors and non-donors15. 
Furthermore, how many times each control was used was not stated. The authors replied 
that this technique has been established and that a specifically designed bootstrap was 
created to estimate the variance31.
Future perspectives
Live kidney donors are individuals who are not patients themselves, and submitting 
them to a surgical procedure stretches the Hippocratic oath taken by physicians. Al-
though the absolute risks for donors following donation are very low, increased risks 
seem to exist among live kidney donors compared to non-donors. Risks both during 
and after donation are taken for granted by live kidney donors to help patients with 
ESRD32. Reduced risk of lifetime dialysis, improved quality of life, and prolonged survival 
are gained by the recipients1. Furthermore, transplantation is far more cost-effective 
than dialysis33,34. Nevertheless, these benefits for kidney transplant recipients should not 
outweigh the risks for live donors after donation. Therefore, future studies should focus 
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on long-term outcomes following donation in which the risks for donors are taken into 
consideration against the risks for comparable non-donors.
CONCLUSION
We conclude that recently published papers still face bias that could have led to a po-
tential overestimation of risk additional to donation. Even if risks are elevated among 
live kidney donors compared to non-donors, the absolute risks for donors following 
donation are very low and should therefore not discourage potential donors. Strong 
points of recent analyses compared to initial analyses are the extended time of follow up 
after donation, large sample sizes and better analysis, hence increasing the reliability to 
estimate potential risks for living kidney donors on the long-term. Key problems remain 
such as that donors are a pre-screened healthy selection of the general population, 
making it difficult to find an equal healthy unscreened comparison group. Specifically, 
not all required clinically relevant data are available for potential comparison groups. 
Selecting a healthier comparison group overestimates the risk additional to donation. 
Future studies should focus on equal inclusion criteria for donors and non-donors, and 
in the analysis, follow-up duration, matched sets, and low absolute risks among donors 
should be accounted for when choosing the statistical technique. Ideally, long-term 
outcomes should uncover risk estimates for potential donors and how these risks would 
change if an individual becomes a live kidney donor.
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ABSTRACT
Previously reported short-term results after live kidney donation show no negative 
consequences for the donor. The incidence of new-onset morbidity takes years to 
emerge, making it highly likely that this will be missed during short-term follow-up. 
Therefore, evidence on long-term outcome is essential. A 10-year follow-up on renal 
function, hypertension, quality of life (QOL), fatigue, and survival was performed of a 
prospective cohort of 100 donors. After a median follow-up time of 10 years, clinical 
data were available for 97 donors and QOL data for 74 donors. Nine donors died during 
follow-up of unrelated causes to donation, and one donor was lost to follow-up. There 
was a significant decrease in kidney function of 12.9 ml/min (P < 0.001) at follow-up. 
QOL showed significant clinically relevant decreases of 10-year follow-up scores in SF-36 
dimensions of physical function (P < 0.001), bodily pain (P = 0.001), and general health (P 
< 0.001). MFI-20 scores were significantly higher for general fatigue (P < 0.001), physical 
fatigue (P < 0.001), reduced activity (P = 0.019), and reduced motivation (P = 0.030). 
New-onset hypertension was present in 25.6% of the donors. Donor outcomes are excel-
lent 10 years post-donation. Kidney function appears stable, and hypertension does not 
seem to occur more frequently compared to the general population.
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INTRODUCTION
In the last two decades, live donors have rapidly become a major source of kidney trans-
plants. The benefits for the recipients of live kidney donor transplantation are clear and 
include superior transplant quality and timing of the transplantation. While the donor 
is not the patient, he or she is willingly exposed to harm of the surgical procedure to 
improve the well-being of another individual. Laparoscopic donor nephrectomy has 
become the standard of care for live kidney donors1–3. This approach has proven to limit 
discomfort, shorten length of hospital stay, and enable faster recovery with less fatigue 
and better quality of life (QOL) up to 1 year after donation4. As opposed to recipients, 
donors are often discharged from further follow-up within months after the operation. 
Data on kidney function are scarce. However, it is unlikely that the donors’ kidney func-
tion will differ from the kidney function of patients who underwent nephrectomy for 
other indications. Reports on quality of life show a significant difference 1 year post-
donation between different surgical techniques4. However, long-term results are rare. 
Most studies lack baseline data, have a retrospective design, and do not have a prospec-
tive long-term follow-up. To establish the surgical standard of care in this era, we con-
ducted a randomized controlled trial comparing laparoscopic and mini-incision open 
donor nephrectomy (MIDN) between 2001 and 2004. We previously reported short-term 
results 3–5 years after donation, demonstrating no difference between different surgical 
techniques in kidney function, quality of life, and mortality5. However, the occurrence of, 
for example, cardiovascular diseases take years to emerge. With donors being a group 
of selected healthy individuals, it is highly likely that this will be missed during a short-
term follow-up of less than 10 years. Recent studies demonstrated an increased risk in 
end-stage renal disease6 and mortality7 compared to non-donors. Therefore, evidence 
on long-term outcome is essential. We now present the prospective data of aforemen-
tioned donors who have been followed up annually, with a long-term follow-up of over 
a decade after donation to evaluate their kidney function, the incidence of new-onset 
hypertension, mortality, and quality of life.
PATIENTS AND METHODS
Study population
All 100 donors of our randomized trial comparing laparoscopic and mini-incision open 
live donor nephrectomy were included4,5. All donors have preoperatively been screened 
by a nephrologist, surgeon, social worker, and an anesthesiologist, and underwent 
imaging by angiography, MRI, or ultrasonography to evaluate the vascular anatomy of 
both kidneys. If both kidneys were deemed suitable, the right kidney was procured for 
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transplantation. The pre-, intra-, and post-operative procedures were described previ-
ously4. An amendment to the protocol was written and approved by the internal medical 
ethics committee to evaluate the 10-year follow-up data of all donors, and a description 
of the ethical guidelines was followed. Donor survival was checked in the Municipal Reg-
istry; 10 years after donation, all donors who were still alive were contacted by mail and 
telephone to fill out questionnaires on their quality of life and fatigue. Of the deceased 
donors, the date and cause of death were recorded. Other outcomes were derived from 
current medical records (Fig. 1).
(N=100) 
(N=100) 
(N=100) 
(N=100) 
(N=100) 
Surgery (N=100) 
QOL (N=89) 
1-year follow-up 
(N=95) 
3-5-year follow-up 
(N=94) 
10-year follow-up 
(N=90) 
MIDN (N=50) 
and 
LDN (N=50) 
 
QOL (N=72) 
QOL (N=74) 
Figure 1. Flowchart of follow-up of100 randomized live kidney donors. The follow-up boxes correspond 
with thenumber of donors of whom annual data on their kidney function and bloodpressure were avail-
able. The quality of life (QOL) boxes represent the numberof donors with available data on quality of life.
Surgical procedures
Donors were operated in two Dutch tertiary referral centers of which 50 were random-
ized to MIDN and 50 to laparoscopic donor nephrectomy (LDN). Both techniques have 
been described previously4.
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Data collection
After discharge, the donors visited the outpatient clinic for a follow-up at 3 weeks, 2 
months, 3 months, and 1 year. Thereafter, a yearly visit to the outpatient clinic was ad-
vised to evaluate kidney function. All donors have prospectively been followed since do-
nation. Data on serum creatinine, blood pressure, weight, used medication, and medical 
history were collected from the medical records. Hypertension was defined according 
to the World Health Organization definitions: For donors aged <45 years: systolic blood 
pressure >140 mmHg and/or diastolic blood pressure >90 mmHg; for donors aged >45 
years: systolic blood pressure >160 mmHg and/or diastolic blood pressure >95 mmHg; 
and/or for both age groups, the use of antihypertensive medication8. The estimated glo-
merular filtration rate (eGFR) was measured according to the Cockcroft-Gault formula9.
To evaluate the physical and psychosocial outcome among the donors, they were asked 
to fill out validated questionnaires on QOL (Short Form-36; SF-36) and fatigue (multi-
dimensional fatigue inventory-20; MFI-20). Previously, these questionnaires had been 
conducted preoperatively, at 1 month, 3 months, 6 months, 1 year, and once between 
3 to 5 years4,5. For the current study, questionnaires to all donors were sent between 
2011–2014 at ten years after donor nephrectomy. The SF-36 is a validated and commonly 
used scale to measure health-related QOL in eight health domains: physical function, 
role limitations due to physical health problems, bodily pain, general health, vitality, so-
cial functioning, role limitations due to emotional problems, and mental health. Scores 
for each of these domains range from 0 to 100, with higher scores indicating better 
QOL10. The MFI-20 includes 20 items ranging from one to five, which are divided into 
five scales: general fatigue, physical fatigue, reduced activity, reduced motivation, and 
mental fatigue. The total score per scale ranges from 4 (no fatigue) to 20 (exhausted)11,12.
Statistical analysis
Continuous variables were compared with the Mann–Whitney U-test, categorical vari-
ables with the chi-square test, repeated variables of the SF-36 and MFI-20 with SPSS 
mixed models, and other repeated continuous variables (including between-group 
analysis) with the paired-samples t-test. Repeated measures of the SF-36 and MFI-20 
were adjusted for baseline values and donor’s gender and age. A five-point difference 
between baseline and follow-up on any health concept of the SF-3613 and a ten-point 
difference between baseline and follow-up of the MFI-2014 were considered minimal 
clinically relevant difference. Survival was analyzed with a Kaplan–Meier analysis, and 
between-group analysis was performed with a log-rank test. All analyses were con-
ducted using SPSS (version 22, SPSS Inc., Chicago, IL, USA). A P-value <0.05 (two-sided) 
was considered statistically significant.
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RESULTS
Between November 2001 and February 2004, donors were randomly selected into two 
groups: 50 for MIDN and 50 for LDN. The follow-up period was between November 2011 
and February 2014. Ninety percent of the initial cohort was alive at 10-year follow-up. 
Donor response rates with regard to the forms increased from 72% at 3–5 years post-
donation to 80% at 10 years post-donation. One donor lives abroad and was lost to 
follow-up. Therefore, annual data on kidney function and blood pressure were available 
in 90% of the donors. Median follow-up of the population was 10 years (range 2–11 
years). Baseline characteristics of the responders are shown in Table 1.
Kidney function
As expected, the 10-year follow-up measurements of eGFR were significantly lower 
compared to the baseline measurements, median 76.6 and 89.5 ml/min, respectively 
(P < 0.001), resulting in a median eGFR loss of 14%. However, the 10-year follow-up 
measurements of the eGFR of all donors were not significantly different compared to the 
1-year measurements, median 76.4 and 76.1 ml/min, respectively (P = 0.858). Seventeen 
donors (18.8%) had an eGFR between 30 and 60 ml/min. Within this group, eGFR at 
baseline was significantly lower when compared to donors with an eGFR of 60 ml/min 
or more, a median of 60 and 94 ml/min, respectively (P < 0.001). Also, age at follow-up 
was significantly higher in this group, a median of 75 and 57 years, respectively (P < 
0.001). No significant differences with regard to body mass index (BMI), gender, and pre-
existent or new-onset hypertension were observed within this group.
Table 1. Long-term outcomes of donor and recipient. Categorical data are given as numbers (%) and con-
tinuous variables as median (range).
Donor
Female (%) 37 (50%)
Age at baseline (years) 49.0 (20-77)
eGFR (ml/min) p <0.001
Baseline 89.5 (29.3)
Follow-up 76.6 (26.6)
Hypertension (%)
Baseline 9 (9%)
New onset 23 (26%)
BMI (kg/m2) p <0.001
Baseline 25.9 (4.0)
Follow-up 27.2 (4.3)
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After 10 years, 35 donors (38%) lost over 6–34% of their creatinine levels as compared to 
their 1-year follow-up. Within this group, creatinine at follow-up was significantly lower 
when compared to donors who lost less than the expected 5% of their creatinine, a me-
dian of 98.5 and 112.5 ml/min, respectively (P = 0.004). None of the donors developed 
end-stage renal disease (ESRD) or required renal replacement therapy.
Incidence of hypertension
The median systolic blood pressure at follow-up was 130 mmHg compared to 128 
mmHg before donation (P = 0.622). Donors who did not develop hypertension had a 
median systolic blood pressure of 125 mmHg at follow-up, which was not statistically 
significantly different as compared to their systolic blood pressure of 124 mmHg at base-
line (P = 0.359).
Hypertension pre-existed in nine donors, who were all treated medically, and of which, 
four donors were involved in a living-related kidney transplantation (P = 0.064). These 
donors had well-regulated hypertension at follow-up. Their median systolic pressure at 
follow-up was 133 mmHg, which had not increased compared to their systolic blood 
pressure of 140 mmHg at baseline (P = 0.307). One donor still had the same medication, 
three donors received one additional antihypertensive drug, two donors received two 
additional antihypertensive drugs, and the other three had switched to other antihyper-
tensive drugs. These donors had a median eGFR of 69.0 ml/min at follow-up.
Twenty-three donors (25.6%) developed high blood pressure 10 years (818 person-years) 
post-donation, of whom 13 donors were involved in a living-related kidney transplanta-
tion (P = 0.708). The recipients of six of these donors (46%) were treated for hypertension. 
There was no significant difference between the incidence and prevalence of hyperten-
sion among recipients compared to donors with pre-existing hypertension (P = 0.682). 
Hypertension of all 23 aforementioned donors was adequately treated with medication. 
Their median systolic pressure was 135 mmHg, which was not different compared to their 
systolic blood pressure of 133 mmHg at baseline (P = 0.826). Ten donors were treated 
with one antihypertensive drug, 10 donors with two antihypertensive drugs, and two 
donors with three antihypertensive drugs. Data were missing in one case. These donors 
had a median eGFR at follow-up of 68.7 ml/min, and the median eGFR in the group 
of donors without hypertension was 79.9 ml/min (P = 0.109). Donors who developed 
hypertension were significantly older at time of donation when compared with donors 
who did not develop hypertension, mean age of 57 vs. 45 years, respectively (P = 0.001). 
No significant differences with regard to eGFR at baseline or 1 year after donation and 
BMI at baseline or follow-up were observed.
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QOL and Fatigue
Previous follow-up results showed that all dimensions of QOL had returned to base-
line5; however, 10-year follow-up scores of the following dimensions were significantly 
decreased compared to baseline: physical function domain (-7.0, P < 0.001), bodily pain 
(-7.0, P = 0.001), general health (-7.1, P < 0.001), and vitality (-4.1, P = 0.028) (Table 2). 
However, the latter was not clinically relevant13. The SF-36 physical functioning devel-
opment during 10 years of follow-up of the donors in comparison with the psychical 
functioning of the general Dutch population of 41–60 years15 is shown in Fig. 2a. After 
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Figure 2. SF-36 physical function dimension of donors and general Dutch population (A) and MFI-20 phys-
ical fatigue of donors and general population (B) development during 10 years of follow-up. Points indicate 
estimate with 95% confidence interval.
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10 years of follow-up, the donors had a physical functioning score above the average of 
the general Dutch population. Compared to the 5-year follow-up, the scores for general 
health and social functioning at 10-year follow-up showed a statistical difference of -5.1 
(P = 0.013) and -4.9 (P = 0.036), respectively.
Table 2. Quality of life of 74 live kidney donorsa fter ten years past donation. Raw data at baseline and 
ten-year follow-up [estimate (SD)]. Estimated adjusted difference between baseline and ten-year follow-
up, 95% confidence intervals and p-values for the dimensions of the SF-36 and MFI-20 scales during ten 
year follow-up. For the SF-36 dimensions overall scores from the general population with similar age are 
provided [estimate (SD)].
Dimension baseline ten-year 
follow-up
general 
population
Estimated 
difference1
95 % 
Confidence
p-value1
SF-36
Physical function 92.5 (13.1) 85.5(16.0) 84.0(19.6) -7.0 -10.9 to -3.2 <0.001
Role physical 91.1 (24.7) 89.0 (30.1) 74.5 (36.8) -1.4 -9.6 to 6.7 0.728
Bodily pain 95.0(13.6) 88.0(16.7) 71.8 (24.1) -7.0 -11.3 to -2.8 0.001
General health 85.1 (13.7) 78.2(15.5) 69.7 (20.6) -7.1 -10.8 to -3.4 <0.001
Vitality 79.9(15.0) 75.8(17.0) 68.6 (20.2) -4.1 -7.8 to -0.5 0.028
Social functioning 90.0(15.6) 89.2(17.3) 83.5 (22.1) -0.8 -4.9 to 3.4 0.716
Role emotional 90.0 (24.1) 91.8 (27.8) 81.6 (33.2) 2.4 -5.2 to 10.0 0.539
Mental health 81.1 (13.2) 82.4(13.8) 75.6(18.5) 1.3 -1.5 to 4.1 0.345
MFI-20
General fatigue 6.0 (3.0) 8.3 (3.9) 8.4 (3.4) 2.2 1.4 to 3.1 <0.001
Physical fatigue 5.5 (2.5) 7.4 (3.4) 7.9 (3.7) 2.0 1.2 to 2.8 <0.001
Reduced activities 6.8 (3.1) 7.8 (3.6) 7.9 (3.5) 1.0 0.2 to 1.8 0.019
Reduced motivation 6.3 (2.5) 7.2 (3.3) 7.8 (3.1) 0.8 0.1 to 1.5 0.030
Mental fatigue 7.4 (4.0) 7.5 (3.9) 7.5 (3.2) 0.1 -0.7 to 0.9 0.807
1 Baseline compared with ten-year follow-up
On average, donors did not return to baseline during 10-year follow-up for any dimen-
sion of the MFI-20: general fatigue (+2.2, P < 0.001), physical fatigue (+2.0, P < 0.001), 
reduced activity (+1.0, P = 0.019), and reduced motivation (+0.8, P = 0.030), with the 
exception of mental fatigue (+0.1, P = 0.807) (Table 2). However, none of these differ-
ences were clinically relevant [14]. The MFI-20 physical fatigue development during 10 
years of follow-up is shown in Fig. 2b. Compared to the 5-year follow-up, the reduced 
activity score shows a statistical difference of -1.2 (P = 0.012). All follow-up dimension 
scores are either better or similar as compared to the general population scores.
Mortality
Nine donors have died according to the longest follow-up. The overall donor survival is 
depicted in Fig. 3. One donor died after 2 years of follow-up due to a car accident, one 
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died after 4 years of follow-up of metastasized colon cancer, two died after 7 years of 
follow-up of which one due to metastasized breast cancer and the other of metastasized 
lung cancer, one died after 8 years of follow-up due to a cerebral vascular incident, one 
died after 9 years of follow-up due to recurrence of breast cancer, two died after 10 years 
of follow-up of which one to an aspergillus infection during chemotherapy for acute 
myeloid leukemia and the other one of a cutaneous malignancy, and one died after 11 
years of follow-up due to a ruptured aneurysm of the descending aorta. Of the six donors 
who died due to malignancies, three donors were related to their recipient. One donor 
donated to her brother and was diagnosed at age 48 with metastasized breast cancer, a 
second donor donated to his son and was diagnosed at age 60 with metastasized colon 
cancer, and the last donor also donated to his son and was diagnosed at age 68 with 
metastasized lung cancer. None of these donors were tested for genetic origin of their 
malignancies.
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Figure 3. Longest follow-up survival of donors. The numbers at risk are shown on the x-axis.
LDN versus MIDN
There was no significant difference between MIDN and LDN donors on the availability 
of their annual data of kidney function and blood pressure (46 vs. 44) or response rate 
(37 vs. 37). Neither baseline characteristics including gender, age, eGFR, pre-existent 
hypertension, and BMI nor long-term results of eGFR, new-onset hypertension, BMI, 
QOL, fatigue scores, and survival of recipient and graft were different between groups.
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DISCUSSION
This prospective study for which data have been gathered during regular, annual, long-
term follow-up of donors participating in a randomized controlled trial includes QOL 
and fatigue scores and data on renal function, hypertension, BMI, and survival. After 10 
years of follow-up, we expected that surgical technique would not influence long-term 
outcomes. This hypothesis holds. Rather interesting is the outcome of the whole group. 
Long-term outcome of live donor nephrectomy is excellent from the perspectives of 
both donor and recipient. The donor retains good quality of life and sufficient kidney 
function. The recipient has a good chance of 10-year survival with a functioning graft. 
The response rate was excellent with 80 percent. As the cohort was randomized, baseline 
characteristics were not expected to significantly differ between groups. On average, 
live kidney donors have excellent life expectancy, do not have to fear further deteriora-
tion of kidney function or an increased risk of hypertension, and have a better quality of 
life than the general Dutch population15. To our knowledge, all other studies have been 
conducted with a retrospective design. QOL has been polled at different times from 
donation and analyzed without paired control data in particular.
The median eGFR 10 years after donation was 76.6 ml/min. These results are in line with 
other studies reporting on a median follow-up of approximately 10 years with similar 
age range of the donors on follow-up16–21. Of all donors, 18.8% have an eGFR between 30 
and 60 ml/min, which is a higher percentage compared to a study by El-Agroudy et al.22 
of 0.9%. However, as baseline eGFR values were higher in the study by El-Agroudy et al., 
post-donation values were expected to be higher and the mean age of their donors is 
less than our donors. Furthermore, the group of donors with an eGFR between 30 and 60 
ml/min comprised significantly older donors and donors with an inferior eGFR at base-
line. It has been established that nephrectomy will lead to a compensatory increase in 
eGFR in the remaining kidney to 70% of pre-nephrectomy values23. Donors with low pre-
operative eGFR before nephrectomy are associated with a low eGFR at follow-up16,18,20,24. 
Najarian et al.25 showed a significant decline in creatinine clearance of live kidney donors 
after a mean follow-up of 16 years compared with baseline; however, these results did 
not significantly differ compared to the siblings of these donors. Therefore, the observed 
decrease in eGFR in our study was expected and in accordance with previous reports. 
Two studies reported an increased risk of ESRD for donors compared with non-donors. 
Mjoen et al.7 reported an increased risk after a median follow-up of 15.1 years among 
1.901 donors, which was likely caused by hereditary immunological kidney disease. 
Muzaale et al.6 reported an increased risk of ESRD for donors compared with matched 
healthy non-donors after a median follow-up of 7.6 years. This study was performed in 
a much larger cohort of 96.217 donors. However, the increased risk was relatively small 
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and the median follow-up was less than 10 years. Our donors have an annual follow-up 
on their kidney function, and as opposed to most other studies, we are able to report 
that eGFR is stable over time at various time points during follow-up. Most other studies 
did not include this continuous follow-up on eGFR and reported on a single time point. 
This might be a reason why the kidney function of our donors remains stable. Kidney 
function deterioration could be detected and monitored at an earlier stage, and if neces-
sary, further investigation can be carried out.
Of all donors, 25.6% were diagnosed with new-onset hypertension. In the current literature, 
the hypertension rate among live kidney donors after approximately 10 years of follow-up 
ranges from 8.8% to 48.6%19,20. Our results are similar to the majority of the existing litera-
ture on live kidney donors16,18,22,26,27. Vasan et al.28 showed that in their population-based 
study, the incidence of new-onset hypertension in their cohort with a mean age of 52 
years was 19% after a follow-up of 4 years. Also, with age the incidence of hypertension 
increased, especially in elderly due to the longer exposure time to develop hypertension. 
These findings are similar to other concordant literature on population-based studies, 
where the incidence of new-onset hypertension ranged from 20% to 30% after a follow-up 
of 4 years29–31. Other studies with a longer follow-up up to 10 years showed an incidence 
of new-onset hypertension of 19–28%32,33. These results of non-donors are concordant 
with our findings. Donors with new-onset hypertension have a mean eGFR of 69.8 ml/
min, which is relatively good. All donors had well-regulated hypertension. El-Agroudy et 
al. show a better mean eGFR in their hypertensive donors, in their cohort, but this cohort 
had higher baseline values and were of younger age. BMI of our donors at follow-up was 
27.2 (4.3), which is comparable with the current literature17,22. The existence of prevalent 
and incident hypertension of donors was not associated with the existence of prevalent 
hypertension among the recipients. In order to assess the incidence of decreased kidney 
function and hypertension after donation compared to the incidence in the general popu-
lation, a matched study comparing live kidney donors and healthy non-donors is required.
Quality of life in general was excellent, and all SF-36 scores were above the average of 
the general Dutch population of 41–60 years15. Previous follow-up results showed that all 
dimensions of QOL had returned to baseline5. However, current results show that donors 
deviate from their baseline value for the dimensions on physical functioning, general 
health, bodily pain, and vitality of the SF-36. Most of the MFI-20 scores with the exception 
of mental fatigue also deviate from the baseline value. However, the average scores are 
similar to a sample of the general population of 40–59 years34,35. The question remains 
whether this may be considered a general effect of aging, as it has been established that 
QOL and fatigue depend on age and gender10,34 or that the measured decrease is the result 
of living with one kidney. The first explanation might be most likely, as the entire cohort 
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is 10 years older and one would expect all described changes to come with higher age. 
Although the latter explanation is unlikely, comparison with a matched control group that 
did not donate a kidney is necessary to provide a definite answer to this question.
Of all donors, 9% died within a range of 2–11 years after donation. All donors died of un-
related causes to donation. This percentage is comparable to previously published results 
and comparable to the mortality rate in the general population17,18. Mjoen et al. reported 
an increased cardiovascular and overall mortality among donors compared to non-donors 
after a median follow-up of 15.1 years. Only two donors in our cohort (2%) died of vascular 
causes due to a ruptured aortic aneurysm and a cerebral vascular incident with a kidney 
function of 135 and 108 ml/min within 1 week before their death, respectively. The ma-
jority of the donors (5%) died of malignancies, of which three donors were involved in a 
living-related kidney transplantation. These malignancies did not appear familial cancers 
based on family history and age of onset. Specific screening of recipients for these specific 
malignancies is currently not performed. In the Netherlands, there is a screening program 
for breast cancer and since a year for colorectal cancer. Therefore, it remains unknown 
whether their recipients are at risk to develop a malignancy. However, with regular follow-
up of the recipients, early recognition of symptoms can be detected.
A possible limitation of this study could have been a response bias. Donors who are not 
satisfied with the results of the procedure are less likely to respond to a survey. However, 
as response rates were excellent, even higher than the response rate after 3–5 years 
of follow-up5, it seems unlikely that these limitations have influenced the outcome of 
this study in a major way. Moreover, this cohort of 100 donors is too small to perform 
subgroup analyses on elderly donors and donors with minor comorbidity, and excess 
overall risk of donors. Larger databases should be generated to conduct these analyses. 
Last, there is no age-matched cohort of non-donors with whom the donor cohort can 
be compared with, which limits the statements on kidney function, QOL, and new-onset 
hypertension to population-based studies in the current literature.
CONCLUSION
In conclusion, donor outcomes including QOL and fatigue scores are excellent more 
than a decade after live kidney donation. Potential donors should not fear major nega-
tive changes at the long-term as kidney function appears stable and hypertension does 
not seem to occur more frequently compared to other live kidney donor studies and 
population-based studies. Recipient outcomes are excellent. These results are reassur-
ing for the current practice of live kidney donation.
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ABSTRACT
To establish the outcome of live kidney donors five years after donation we investigated 
the risk for progressive renal function decline and quality of life (QoL). Data on estimated 
glomerular filtration rate (eGFR), creatinine, hypertension, QoL, and survival were as-
sessed in a prospective cohort of 190 donors, who donated between 2008-2010. Data 
was available for >90%. The mean age pre-donation was 52.8±11.5years, 30 donors 
having pre-existent hypertension. The mean follow-up was 5.1±0.9 years. Eight donors 
had died due to non-donation related causes. After five years the mean eGFR was 60.2 
(95%CI 58.7-62.7) ml/min/1.73m2, with a median serum creatinine of 105.1 (95%CI 
102.5-107.8) μmol/L. eGFR decreased 33.6%; and was longitudinally lower among men 
than women and declining with age (p<0.001), without any association on QoL. Donors 
with pre-existent and new-onset hypertension demonstrated no progressive decline of 
renal function overtime compared to non-hypertensives. No donors were found with 
proteinuria, microalbuminuria or at risk for end-stage renal disease. After an initial 
decline post-donation, renal function remained unchanged overtime. Men and ageing 
seem to affect renal function overtime, while decreased renal function did not affect 
QoL. These data support further stimulation of living kidney donation programs as seen 
from the perspective of donor safety.
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INTRODUCTION
Renal transplantation offers a better prognosis and long-term benefit to patients with 
chronic kidney failure compared with other renal replacement therapies1, 2. The benefits 
of live kidney donation have been well-described3-6 and the surgical procedure has been 
proven to be safe7-13 with a very low mortality rate13, 14. In addition, health related quality 
of life of donors after the procedure has proven to be better than of the general popula-
tion7, 8, 10, 15, 16. Driven by its success the inclusion criteria of the living donation program 
gradually have been extended and older donors and donors with minor co-morbidities 
such as hypertension and obesity have become eligible for donation17-20.
However, it must be noted that live donor nephrectomy is performed on people con-
sidered to be healthy individuals who do not need any intervention. Therefore, seeking 
after optimal donor safety remains priority in living kidney donation for the short as 
well as the long-term. It has been documented that renal function usually may decline 
directly after donation and recovers within the first year. Previous studies suggest that 
renal function reached at one year post-donation remains stable at least for over the 
next decade16, 21, 22, but then declines with ageing21. These studies report on cohorts 
including low numbers of donors with minor co-morbidities, such as hypertension and 
obesity. Therefore, the outcome of these studies may not apply for donors under the 
donor eligibility criteria used at present.
Previously, we have reported on the one year follow-up of a donor cohort from a ran-
domized study on hand-assisted or laparoscopic donor nephrectomy 10. Donors were 
included with hypertension and overweight. We now present data of five-year follow-up 
and analyzed the effect of potential factors associated with accelerated decline of renal 
function. In addition, we longitudinally studied the effect of renal function on health 
related quality of life of live kidney donors.
PATIENTS AND METHODS
Study population
All 190 donors of a randomized controlled trial comparing left-sided hand-assisted and 
laparoscopic donor nephrectomy conducted between July 2008 and September 2010 at 
the Radboud University Medical Center, Nijmegen and the Erasmus University Medical 
Center, Rotterdam were selected10, 23. The pre-, intra- and post-surgery procedures were 
described previously10, 23. An amendment to the protocol23 was written and approved 
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by the internal medical ethics committee to evaluate the five-year follow-up data of all 
donors (MEC-2015-653), and a description of the ethical guidelines were followed.
Surgical procedures
Donors were operated in two Dutch tertiary referral centers of which 95 were random-
ized to hand-assisted and 95 to laparoscopic donor nephrectomy. Both surgical tech-
niques have been described previously23.
Data collection
Yearly visits to the outpatient clinic or the general practitioner were scheduled. All donors 
have prospectively been followed since donation. For this study, data were collected 
from medical records five years after the randomized controlled trial had ended. The data 
collection included serum creatinine, proteinuria, microalbuminuria, blood pressure, 
weight, hypertension, medication, and donor survival. A creatinine based estimated 
glomerular filtration rate (eGFR) was measured with the CKD-EPI equation24. Proteinuria 
was defined as a protein-creatinine ratio of >45 mg/mmol25 and microalbuminuria as an 
albumin-creatinine ratio of >30mg/mmol26. Blood pressure was manually measured in 
an upright position in the exam room on one arm. Hypertension was defined as listed as 
diagnosis in medical records, the use of antihypertensive medication or repeated high 
blood pressure measurements. Donor survival was checked in the Municipal Registry up 
to November 13th, 2015 and, if applicable, the date and reason of death was recorded.
Quality of life measures
We used a physical and mental instrument to assess the quality of life, both represented 
in the Short Form health questionnaire, a validated and commonly used tool to measure 
health related quality of life. It contains questions on physical performance and well-
being, and mental functioning and emotional well-being, resulting in the physical (PCS) 
and mental component score (MCS) respectively. The SF-12 can be extracted from a 
SF-3627, 28. The component scores are computed by normative comparison and standard-
ized to the Dutch population29, 30. Scores below 50 indicates inferior QoL compared to 
the general Dutch population and scores above 50 indicates superior QoL. The EQ-5D 
records QoL in five dimensions: mobility, self-care, daily activities, pain or discomfort, 
and anxiety/depression. The responses on the five dimensions combine to a score be-
tween -0.59 (worst imaginable health state) and 1.00 (best imaginable health state)31. 
The SF-36 and EQ-5D questionnaires had been conducted preoperatively at one, three 
and six months, and one year10. For the current study SF-12 and EQ-5D questionnaires 
were sent to all donors who were still alive five years after the trial had ended.
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Statistical analysis
The difference between baseline and follow-up were compared with paired T-tests for 
continuous normally distributed variables, Wilcoxon’s tests for abnormally distributed 
variables and the Chi-square tests for categorical variables.
Mixed modeling, also referred to as multilevel regression analysis, was applied for longi-
tudinal analyses of renal function and health related QoL. Multilevel regression analysis 
can efficiently handle data with unbalanced time points and corrects for selective drop-
out when the dropout is dependent on aspects that are included in the model32. First, 
saturated models were postulated for each of the dependent variables eGFR, creatinine, 
PCS, MCS, and EQ-5D. The saturated models included age, gender, BMI, pre-existent 
hypertension, new-onset hypertension, PCS, MCS, and EQ-5D, time, linear, and logarith-
mic and all interactions with time as fixed effects. The time variables were entered as 
continuous variables. The deviance statistic33 using restricted maximum likelihood34 was 
applied to determine the most parsimonious covariance structure (unstructured, vari-
ance components or intercept only). The saturated model was subsequently reduced by 
eliminating insignificant fixed effects, taking into account that interaction effects ought 
to be nested under their respective main effects35. The significance of the difference 
between the saturated model and the parsimonious final model was determined with 
the deviance statistic using ordinary likelihood. Effect sizes (Cohen’s d) were computed 
by dividing the difference between the estimate at time point t and the baseline score 
by the estimated baseline standard deviation. An effect size between 0.20 and 0.50 was 
considered a small effect, between 0.50 and 0.80 a medium effect and above 0.80 a large 
effect36. All analyses were conducted using SPSS (version 22, SPSS Inc., Chicago, USA). 
Two sided p-values <0.05 were considered statistically significant.
RESULTS
Population characteristics
The living kidney donation procedures were conducted in 93 (48.9%) living-related and 
97 (51.1%) non-related donor-recipient combinations. Thirty-two percent of the donors 
(n=61) had (multiple) extended eligibility criteria: pre-existent hypertension (n=30), 
age >70 years (n=10), and BMI >30 kg/m2 (n=26). The follow-up examinations were per-
formed between November 2015 and January 2016. Eight donors had passed away due 
to non-donation related causes; three out of these eight donors had completed a 5-year 
follow-up. Five donors were lost to follow-up: one donor lives abroad and four donors 
were not willing to visit the outpatient clinic for the annual follow-up. Thus, follow-up 
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data was available in more than 90.0% of donors. Mean follow-up of the population was 
5.1±0.9 years. Population characteristics are shown in Table 1.
Table 1. Population characteristics pre-donation and at 5-year follow-up
Pre-donation 
(N=190)
5-year
(N=176)
N mean±s.d./
median [IQ-range]/
frequencies (%)
N mean±s.d./ 
median [IQ-range] 
frequencies (%)
p-value
Age (years) 190 52.8±11.5 176 58.0±11.1 -
Gender (male) 190 92 (48.4%) 176 82 (46.6%) -
Caucasian 190 183 (96.3%) 176 170 (96.6%) -
Creatinine (μmol/L) 190 74 [64 - 83] 173 104 [91 - 118] p <0.001
eGFR (ml/min/1.73m2) 190 91.9±15.0 173 60.2±12.1 p <0.001
BMI (kg/m2) 190 25.9 [23.8 - 28.5] 157 26.7 [24.5 - 30.1] p <0.001
Systolic blood pressure (mmHg) 189 130 [120 - 144] 167 134 [120 - 145] p =0.407
Diastolic blood pressure (mmHg) 189 79 [73 - 85] 167 80 [75 - 85] p =0.005
Hypertension* 170 30 (17.6%) 169 59 (34.7%) p <0.001
Physical component score (PCS) 178 58.4 [55.8 - 59.8] 169 52.3 [48.3 - 55.5] p <0.001
Mental component score (MCS) 178 54.4 [52.1 - 56.4] 169 44.2 [40.0 - 49.0] p <0.001
EQ-5D score 188 1.00 [1.00 - 1.00] 167 1.00 [0.84 - 1.00] p =0.350
*defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg and/or the use 
of antihypertensive medication
Renal function
Only gender and age turned out to have significant effect on eGFR (Table 2). After 
one year, eGFR values for women decreased significantly with 31.8%, and thereafter 
remained stable during five years after donation (Table 3). Men had at baseline a small 
but significantly higher eGFR than women, which decreased with 32.5% after one year, 
and decreased further to 35.1% after five years. Older patients (e.g. age 10 years older) 
had lower baseline values, but recovered slightly at the one and five year follow-up. 
Overall, the five-year follow-up measurements of eGFR compared with the pre-donation 
measurements, demonstrated a mean decline in eGFR of 33.6%. Longitudinal analysis 
showed no effect of new-onset hypertension and BMI on eGFR (data not shown). Fur-
thermore, no different outcome in eGFR (p=0.479) or eGFR decline (p=0.159) was found 
in donors with extended eligibility criteria (n=61) as compared with donors without 
these criteria.
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Also for creatinine gender and age were found to have significant effects on renal func-
tion (Table 2). After one year, creatinine values for women increased significantly with 
40.6%, but this reduced to 35.7% five years after donation (Table 3). Men had at baseline 
a small but significantly higher creatinine level than women, which increased with 45.1% 
after one year, and remained stable (43.5%) after five years. Older patients had lower 
baseline values, and these increased slightly at one and five-year follow-up. Overall, the 
five-year follow-up measurements of creatinine compared with the pre-donation mea-
surements, resulted in a mean increase of 39.4%. Longitudinal analysis demonstrated no 
effect of pre-existent and new-onset hypertension, or BMI on creatinine.
The five-year follow-up mean eGFR of men and women are plotted against age catego-
ries (n=±20), as depicted in Figure 1 (See Supplement A for corresponding values). The 
eGFR of the donors are matched to the eGFR of corresponding age categories of the 
general population37. All age categories for men and women demonstrated significant 
differences in eGFR.
Table 2. Parsimonious mixed models predicting renal function and quality of life measures
Model Intercept or main effect Time linear Time logarithmic
estimate standard 
error
estimate standard 
error
estimate standard 
error
eGFR(ml/1.73m2) 90.26 *** 1.06 18.70 *** 0.66 -68.40 *** 1.94
men 1.99 * 0.66 -1.86* 0.83
age -0.83 *** 0.07 -0.13 * 0.06 0.48 ** 0.17
Creatinine (umol/L) 67.57 *** 1.25 -19.41 *** 1.18 67.61 *** 3.33
men 15.42 *** 1.81 -5.74 *** 1.67 22.70 *** 4.75
age 0.16 * 0.07 0.15** 0.05
Physical component score 57.02 *** 0.52 -2.43 ** 0.75 2.69 2.08
men 0.00 0.74 2.71 * 1.08 -6.71 * 3.02
age -0.10 *** 0.03
BMI -0.40 *** 0.09
new-onset hypertension 2.30 * 0.89
Mental component score 52.37 *** 0.58 -3.39 *** 0.58 4.34 ** 1.60
men 1.80 * 0.80
EQ-5D 0.947 *** 0.009 -0.023 * 0.011 0.063 * 0.031
pre-existent hypertension 0.003 0.020 -0.013 * 0.006
BMI 0.005 * -0.007 *** 0.002
All models included age, gender, BMI, and pre-existent and new-onset hypertension for all models. In ad-
dition, PCS, MCS, and EQ-5D for outcome renal function, and eGFR and creatinine for outcome QoL. Only 
significant effects are mentioned.
* p<0.05;  ** p<0.01;  *** p<0.001
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Table 3. Longitudinal analysis of renal function and quality of life
Model Estimates Effect sizes (Cohen’s d)
Baseline 1 year 5 years Baseline - 
1 year
Baseline - 
5 years
1 year -  
5 years
eGFR (ml/min/1.73m2)
women 90.3 61.6 61.2 -2.68*** -2 71 *** -0.03
men 92.2 62.3 59.9 -2.80*** -3.02*** -0.22**
age 10 years older, additional effect11 -8.3 -6.4 -6.4 0.18** 0.18*** -0.00
Creatinine (nmol/L)
women 67.6 95.0 91.7 2.15*** 1.89*** -0.26*
men 83.0 120.4 119.1 2.93*** 2.82*** -0.11
age + 10 years1’ 1.6 2.6 4.2 0.08** 0.21** 0.13**
Physical component score
women 57.0 56.5 49.7 -0.11 -1.45*** -1.34***
men 57.0 54.5 51.2 -0.50** -1.15*** -0.65***
age 10 years older, additional effect11 -1.0 -1.0 -1.0
BMI 5 kg/m2 higher, additional effect11 -2.0 -2.0 -2.0
new-onset hypertension1’ 2.3 2.3 2.3
Mental component score
women 52.4 52.0 43.2
men 54.2 53.8 45.0 -0.06 -1.51*** -1.45***
EQ-5D
no pre-existent hypertension 0.95 0.97 0.95 0.18 0.02 -0.19
pre-existent hypertension 0.94 0.95 0.88 0.07 -0.55* -0.62**
BMI 5 kg/m2 higher, additional effect11 0.03 0.00 -0.04 -0.21*** -0.54*** -0.33***
All models included age, gender, BMI, pre-existent, new-onset hypertension for all models. In addition, PCS, 
MCS, and EQ-5D for outcome renal function, and eGFR and creatinine for outcome QoL. Only significant 
effects are mentioned.
 1) This value must be added to the estimate reported above e.g. the eGFR estimate for women at mean age 
(52.3 years) at baseline is 90.3, and the estimate for 10 years older women (i.e. 62.3 years) is 90.3 - 8.3 = 82.0.
* p<0.05;  ** p<0.01;  *** p<0.001   Non-significant effects are deleted
Ninety-three donors had an eGFR <60 ml/min/1.73m2 at five-year follow-up without 
proteinuria (mean protein-creatinine ratio of 11.3±6.9 mg/mmol) or microalbuminuria 
(mean albumin-creatinine ratio of 2.5±4.5 mg/mmol). These donors were older at the 
time of donation (mean 58.3±8.6 versus 47.5±10.6 years, p<0.001) and had a lower eGFR 
pre-donation (mean 82.3±11.5 versus 101.0±10.7 ml/min/1.73m2, p<0.001) than donors 
with a current eGFR of ≥60 ml/min/1.73m2. In addition, their eGFR decline was higher at 
five-year follow-up, mean 36.9±8.6 versus 30.0±7.8 % (p<0.001) respectively. However, 
there were no differences at five-year follow-up in gender (p=0.152) or BMI (p=0.920).
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Figure 1. Overview of mean eGFR values at 5-year follow-up after live kidney donation of male (A) and 
female (B) donors with corresponding eGFR of the general population.
At follow-up none of the donors had proteinuria or microalbuminuria; mean protein-
creatinine ratio was 13.5±24.6 mg/mmol and mean albumin-creatinine ratio 2.0±3.6 mg/
mmol. No donors were found at risk for end-stage renal disease or renal replacement 
therapy. Among the 93 living-related donations, 14.7% of the recipients (n=10) had a he-
reditary renal disease (e.g. Joubert syndrome, polycystic kidney disease). No significant 
differences in eGFR or protein-creatinine ratio were found among living-related donors 
with recipients with a hereditary renal disease and other living-related donors, p=0.408 
and p=0.490 respectively.
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Effect of hypertension on renal function
Blood and urine renal function measures among non-hypertensive and hypertensive 
donors are depicted in Table 4. The eGFR overtime for non-hypertensive and hyperten-
sive donors is depicted in Figure 2.
Table 4. Effect of hypertension on renal function of live kidney donors
Renal function Non-hypertensives 
N=111
Pre-existent 
hypertensives N=30
New-onset 
hypertensives N=29
mean±s.d/medians 
[IQ-range]
mean±s.d/medians 
[IQ-range]
mean±s.d/medians 
[IQ-range]
Blood
eGFR (ml/min/1.73m2) Baseline 94.1 ± 14.8 85.4 ± 12.1 85.9 ± 13.0
1 year 60.7 ± 11.6 54.4 ± 11.3 53.2 ± 10.2
5 year 62.3 ± 12.2 57.6 ± 12.2 54.2 ± 9.7
Creatinine (μmol/L) Baseline 74 [56-92] 76 [58 – 104] 73 [45 – 101]
1 year 106 [81 – 131] 112 [94 – 130] 112 [84 – 130]
5 year 102 [75 – 129] 103 [73 – 134] 119[84- 153]
Urine
Protein-creatinine ratio 5 year 8.7 [2.7 – 14.7] 11.8 [1.8 – 21.8] 8.5 [5.2 – 11.8]
Albumin-creatinine ratio 5 year 0.9 [-0.5 – 2.3] 1.9 [-4.3 - 6.3] 1.4 [0.1 – 2.7]
Thirty donors (17.6%) had pre-existent hypertension compared with 59 donors at follow-
up. The five-year eGFR and serum creatinine of donors with pre-existent hypertension 
was not significantly different from these values of non-hypertensive donors, p=0.062 
and p=0.533 respectively. Donors with pre-existent hypertension were adequately 
treated after donation and showed no abnormalities at follow-up, having a mean 
systolic blood pressure of 138.9±17.6 mmHg and a mean diastolic blood pressure of 
83.5±9.2 mmHg. Treatment consisted of beta blockers (n=16), diuretics (n=12), calcium 
chain blockers (n=5), ACE inhibitors (n=5), ATI inhibitors (n=5), and other (n=1). Ten 
donors used one medication to regulate blood pressure. During follow-up of donors an-
tihypertensive medication was unchanged in nine, dose adaptation or combined drug 
treatment in eight, complete drug substitution in five, cessation of medication in three, 
and dose reduction in two Of two donors it is unknown if the medication has altered 
compared to pre-donation use, and of one donor the use of medication is unknown.
Twenty-nine donors developed new-onset hypertension with a mean systolic blood 
pressure of 141.7±17.3 and a mean diastolic blood pressure of 83.1±7.9 mmHg. They 
were mostly treated with medication, including beta blockers (n=7), diuretics (n=5), 
calcium chain blockers (n=3), ACE inhibitors (n=10), and ATI inhibitors (n=7). One donor 
used three medications, eight donors used two medications, fifteen donors used one 
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medication, four donors did not use medication, and of one donor the number of medi-
cations is unknown. The five-year eGFR and serum creatinine of new-onset hypertensive 
donors were significantly different compared to non-hypertensive donors, p=0.001 and 
p=0.015 respectively, while the eGFR decline was not significantly different 36.6 versus 
33.4 % (p=0.073), respectively. New-onset hypertensive donors were older at the time 
of donation (59.0±8.7 versus 50.4±11.2 years, p<0.001) with a higher BMI (27.6±3.7 
versus 25.9±3.4, p=0.021), and lower eGFR before donation (85.9±13.0 versus 94.1±14.8 
years, p=0.007) compared with non-hypertensive donors. Furthermore, there were more 
donors with an eGFR <60 ml/min/1.73m2 with new-onset hypertension compared with 
non-hypertensive donors, 79.3 versus 43.5% (p=0.001), respectively.
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Figure 2. Renal function (A, eGFR overtime; B, eGFR decline) during follow-up of non-hypertensive, preex-
istent hypertensive, and new-onsethypertensive donors overtime.
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Health related quality of life
Donor response with regard to the quality of life questionnaires was almost 90% of the 
original cohort. PCS and EQ-5D follow-up scores were higher compared with the general 
Dutch population29, 30. MCS scores were lower (Table 1). There were no significant differ-
ences in PCS, MCS and EQ-5D score at five-year follow-up between donors with an eGFR 
<60 ml/min/1.73m2 compared with an eGFR ≥60 ml/min/1.73m2, p=0.993, p=0.754, and 
p=0.242 respectively. There was also no significant difference in MCS at five-year follow-
up among living-related donors for recipient (p=0.837) or graft survival (p=0.894).
Longitudinal analysis of health related quality of life
No change in PCS was observed in women after one year, but they had a large decrease 
five years after donation. Men had a medium decrease at one-year with a further re-
duction at five-year. Older donors and donors with a higher BMI had lower PCS over 
the whole period. Donors who developed new-onset hypertension had higher PCS 
pre-donation and during follow-up. In all donors a large decrease in MSC was observed 
after five years. MCS scores remained stable at one-year follow-up, but showed a large 
decrease at five-year follow-up. Men had slightly higher MCS than women pre-donation 
and during follow-up. Donors had a small decrease in EQ-5D values after one year, but 
this difference was not significant at the five-year follow-up. Donors with a pre-existent 
hypertension had a medium decrease at one and five-year follow-up. Donors with e.g. 5 
kg/m² higher BMI had relatively lower baseline EQ-5D scores, which reduced further to a 
medium decrease at five-year follow-up (Table 3). No significant effect of age or gender 
on EQ-5D scores was found.
Survival
Eight donors died due to non-donation related causes. One donor suddenly died at 
home within one year after donation due to an unknown reason after coughing up 
blood (age 75, unrelated donation); four donors died after 4 years of follow-up, one for 
unknown reason (negative findings at autopsy; age 24, related donation), one due to 
sudden cardiac arrest (age 62, unrelated donation), one due to a malignant mesothe-
lioma (age 67, unrelated donation), and one due to a brain tumor (age 65, unrelated 
donation); two died after 5 years of follow-up, one due to lung cancer (age 56, related 
donation) and one due to sepsis (age 63, related donation); finally one died after 6 years 
of follow-up due to decompensated alcoholic liver cirrhosis (age 66, related donation).
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DISCUSSION
This study reports on a prospective cohort of 190 donors that were followed annually 
after living kidney donation up to five years after the randomized trial had ended. Data 
were available of more than 90% of donors. This study demonstrates a stable renal 
function five years after donation with no progressive decline in function. Also, donors 
with pre-existent and new-onset hypertension do not have a progressive decline dur-
ing follow-up. Furthermore, no proteinuria or albuminuria was observed in any of the 
donors, not even in donors with an eGFR <60 ml/min/1.73 m2. This supports the assump-
tion that live kidney donors are a highly selected group of healthy individuals who may 
safely proceed in life with one kidney and the values on eGFR and creatinine outside 
the normal range for individuals with two kidneys do not indicate any physiological 
dysfunction, since secondary signs of kidney disease such as proteinuria are not present. 
These findings support the recommendation of Matas et al. that kidney donors with 
an eGFR <60 ml/min/1.73m2 should not be classified as having chronic kidney disease, 
especially if there are no other signs of kidney disease present38.
Renal function
Our study demonstrates that lower eGFR after donation is longitudinally associated with 
older age and male gender, and cross-sectionally with lower pre-donation eGFR levels. 
All three factors can easily be explained. The CKD-EPI equation24 used to calculate the 
eGFR, has age and gender embedded in the equation. Therefore, ageing will result in a 
lower eGFR, while the serum creatinine remains stable. This is comparable to the find-
ings in the general population. Second, muscle mass, which is different between males 
and females, influences serum creatinine levels and is therefore responsible for the 
difference in eGFR. Last, there is an expected decline in eGFR levels among donors after 
donation, therefore lower pre-donation eGFR levels will result in lower post-donation 
levels. Thus, by definition donors with a lower eGFR levels will have lower eGFR levels 
at follow-up. In our study no donors had any signs of glomerular dysfunction such as 
proteinuria or microalbuminuria, not even donors with an eGFR <60 ml/min/1.73m2.
Other studies reporting on renal function following donation also reported on a stable 
renal function after one year39-44, with a decline in renal function of 31-40%43, 44. Despite 
that our cohort is older compared with most studies and has included a higher number 
of hypertensive donors with a higher pre-donation eGFR, the decline fits the lower 
range. The renal function of the general population age categories37 was found to be 
higher than our donor cohort. It should be noted that hypertensives were excluded from 
their analysis, which could have led to a higher renal function among the general popu-
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lation. Furthermore, the renal function was calculated using the MDRD45. Nowadays the 
CKD-EPI equation is used, which is more accurate compared with the MDRD equation24.
Effect of hypertension on renal function
Ageing and hypertension are reported to be associated with progressive decline in renal 
function in the general population46-50. These factors are part of the extended eligibility 
criteria of live kidney donors indicating that they would even have an increased risk with 
just one kidney and no renal reserve left. Our study demonstrated that in cross-sectional 
analysis new-onset hypertensive donors have a significant lower eGFR and higher serum 
creatinine at five-year follow-up than non-hypertensive donors, while eGFR decline was 
similar. More importantly, longitudinal analysis demonstrated no effect of new-onset 
hypertension on eGFR. Furthermore, the incidence of hypertension is known to increase 
with age51, which is supported by our finding that hypertensives were significantly older 
compared to non-hypertensives. The used definition of hypertension embeds the use of 
antihypertensive medication52, which could include donors who were prescribed anti-
hypertensive medication for a different indication than hypertension, such as a cardiac 
condition (beta blockers, diuretics, or ACE-inhibitors). The use of antihypertensive medi-
cation can influence the renal function, such as ACE-inhibitors, which could decrease or 
remove proteinuria, or increase serum creatinine, and diuretics, which could increase 
the serum creatinine, resulting in a lower eGFR. This could have affected our renal func-
tion results among hypertensive donors. Reassuringly, as in previous studies40-44, 47, 53, we 
found no evidence of further decline in renal function after one year, no proteinuria or 
albuminuria, and no donors at risk for end-stage renal disease.
Health related quality of life
EQ-5D scores remained at the same level after five years of follow-up. Physical and mental 
component scores decreased after five years, but the PCS remained higher than the gen-
eral population scores30, the MCS at five-year follow-up was lower. The overall decrease 
in all measures overtime is a phenomenon that has also been observed in the general 
population30. It has been established that quality of life depends on both age and gen-
der30, 54. This was true for the PCS where differences were found in age and gender, but 
also in BMI. The latter is known to be associated with a decreased quality of life among 
the general population55, 56. Reassuringly, the PCS was not affected by a decreased eGFR 
<60 ml/min/1.73m2, which is known to decrease physical functioning57. Unfortunately, 
the overall decrease for MCS was larger overtime compared to the general population30. 
This could not be explained by age or BMI. MCS was not affected by recipient or graft 
survival among living related donors. However, some respondents did report to have 
mental difficulties due to problems at work, or death of a partner or family member. This 
might explain the lower MCS for some donors, but this was not a sufficient explanation 
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for the overall lower MCS at five-year follow-up. This may be explained by assuming that 
donors are mentally affected by other (medical) conditions not related to donation or 
life events. It must be noted that while donors are a pre-selected group of individuals, 
their quality of life follow-up scores are within the range of the general population.
Strengths and limitations
The strength of this study is the extensive pre-donation and follow-up data from a 
prospective cohort of live kidney donors, who annually visited a physician and whose 
changes in medical condition were recorded. Only 2.6% of the donors were lost to 
follow-up. Previous studies58, 59 have indicated that donors lost to follow-up are healthier 
than donors attending timed control visits. The quality of life questionnaire response 
was more than 90%, and it seems unlikely that donors who were not satisfied with the 
results of the donation were less likely to respond to the questionnaire. Therefore, both 
limitations could not have influenced the outcome of this study in a major way. A limita-
tion that should be mentioned is the lack of a matched control group of non-donors 
limiting the statements of the decline in renal function, incidence of hypertension, and 
quality of life to population-based studies. Furthermore, the relatively small number of 
donors in our cohort limits us to perform subgroup analysis. Finally, the eGFR used as 
a measurement for renal function is merely an estimation and could underestimate the 
renal function for leaner or bigger persons. Furthermore, the eGFR is less accurate in 
the higher renal function levels. The better the kidney function, the less accurate the 
predictive value of the eGFR. Also, the eGFR is not validated for individuals with a mono 
kidney. A GFR from a 24hrs urine sample would be more accurate.
Future perspectives
Of course, it is possible for donors to develop a medical condition that could cause de-
terioration of the renal function to ESRD11, 12, 60. Two recent studies reported that donors 
have an increased risk for ESRD than non-donors61, 62. While their follow-up was longer 
than our study, the establishment of the results and more importantly the subsequent 
limitations of these studies should be taken into consideration by transplant profes-
sionals before indiscriminately repeating these results to the next potential donor in 
the consulting room. Especially, considering the impact of these studies61, 62 among 
the transplant community. Selection criteria for non-donors were not equal to donors 
leading to a healthier group of non-donors. Furthermore, due to the low incidence of 
ESRD, both analyses overadjusted for potential confounders. Both limitations could 
have led to an overestimation of risk additional to donation63. Reassuringly, both studies 
reported low absolute risks for ESRD among donors, which should be the main message 
for potential new donors. One should bear in mind that donors with a decreased renal 
function are no patients with renal insufficiency. Individuals are categorized as having 
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chronic kidney disease if the eGFR is below 60 ml/min/1.73m2. Furthermore, among 
these individuals secondary signs of kidney disease such as proteinuria are usually 
present. It is unfair to categorize donors within this group, unless other signs of kidney 
disease are present. Annual follow-up of live kidney donors is recommended to detect 
any loss of renal function. Future studies are indicated to identify those individuals at 
risk for a progressive loss of renal function after kidney donation64.
In conclusion, we report a stable renal function after five years of follow-up among 
live kidney donors in the era of extended live kidney donation eligibility criteria, which 
seems to be maintained after an initial decline post-donation. Ageing, gender and 
hypertension seem to be associated with a lower renal function among donors, which 
is similar for the general population. There was no evidence for end-stage renal disease 
among donors or other additional signs of renal dysfunction. These results reassure the 
current practice of live kidney donation and a conscientious follow-up of live kidney 
donors should be maintained after donation. Future studies are indicated to identify 
those individuals at risk for a progressive loss of renal function after kidney donation.
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Supplement A. The 5-year follow-up mean eGFR of male and female donors with the eGFR of correspond-
ing age categories of the general population
Age (years) Donors General population
Male N Mean ±s.d.* N Mean ±s.d.* t(df ) p-value
25-49 23 71.5 ±10.5 642 85.7 ±13.2 6.33(24.6) <0.001
50-59 19 57.0 ±7.9 301 77.4 ±12.5 10.41(24.1) <0.001
60-64 17 58.7 ±9.4 149 75.0 ±15.0 6.29(26.4) <0.001
65-85 21 52.0 ±13.7 441 71.5 ±13.5 6.39(21.9) <0.001
Female
25-49 21 67.7 ±12.0 945 79.5 ±12.5 4.45(21.0) <0.001
50-59 30 62.0 ±10.3 365 71.6 ±12.5 4.80(36.4) <0.001
60-64 14 57.9 ±10.6 180 68.0 ±12.0 3.40(15.7) 0.004
65-85 28 53.5 ±8.7 368 64.9 ±11.0 6.55(33.8) <0.001
* eGFR (ml/min/1.73 m2)
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ABSTRACT
To investigate the kidney selection procedure prior to donation to maximize donor 
safety, we investigated whether ultrasound measurements for kidney volume are com-
parable with CT measurements. Pre-donation volume and increase in kidney size may 
be an important indicator for renal function after donation and subsequent loss of func-
tion. Consecutive donors, with a pre-donation CT-scan, were approached preoperatively 
for additional ultrasound examination. Measurements were independently performed 
by two ultrasonographists (US-1; US-2) and considered accurate when the mean differ-
ences between both ultrasonographists for length, width and thickness of the kidneys 
were <5 mm. Ultrasound volumes were calculated with the ellipsoid equation (length x 
width x thickness x π/6) and an adjusted equation (length x width x thickness x 0.674), 
and CT volumes with the voxel count method, which is considered the gold standard. 
One hundred kidneys were measured. The mean differences between US-1 and US-2 for 
similar measurements were <5 mm. The ellipsoid equation underestimated the volume 
for US-1 with 16.9% and for US-2 with 14.8%, while the adjusted equation overestimated 
the volume with 6.8% and 9.5% respectively. The correlation between CT and ultrasound 
volume with the adjusted equation is strong for both US-1 (r 0.76, p<0.001) and US-2 (r 
0.80, p<0.001). Ultrasound measurements for kidney volume are comparable with CT 
measurements. Therefore, ultrasonography is a reliable modality for live kidney donor 
follow-up monitoring kidney size adaption post-donation.
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INTRODUCTION
Live kidney donation has proven to be the best treatment for patients with end-stage 
renal disease. Live kidney donors are individuals who undergo major surgery for the 
benefit of someone else and it is of utmost importance to minimize the risks of the 
procedure and to maximize donor safety on short as well as long term1. The benefits 
of a living kidney donation program are pre-emptive transplantation, superior organ 
quality and increased graft survival2. These superior results have led to an increase in the 
number of live kidney donations3, 4.
Live kidney donation is possible because of the capacity of the remnant kidney to physi-
ologically compensate for kidney function by hyperfiltration and subsequent increase 
in kidney volume5-11. Increase in volume of the remnant kidney can be considered as 
the physiological response to adapt for the decrease in kidney function. The most ac-
curate measurement for kidney volume, that does not deviate from the actual kidney 
size, is the voxel count method12. Nevertheless, this method always requires the need of 
a dedicated workstation with three-dimensional image processing abilities to generate 
the images, which is currently not widely available13. This raises the question whether 
kidney size estimation after donation or for research purposes would be possible with 
ultrasonography. This would be less time-consuming for health care professionals, and 
would be less harmful and expensive for (study) patients. Furthermore, ultrasonography 
is the first diagnostic imaging modality of choice after donation.
Recently, long-term safety of live kidney donors has been debated14-17. Therefore, follow-
up of kidney size after donation may become an important indicator in the near future. 
To measure kidney volume with ultrasonography the volumetric ellipsoid equation is 
used: length x width x thickness x π/618. Nevertheless, this equation is debated because 
it has proven to underestimate the kidney volume19-22. This has led to the proposed 
adjusted equation by Zakhari et al.22: length x width x thickness x 0.674. To validate 
ultrasound kidney volume measurements for the monitoring of kidney function adap-
tion after donation, we investigated if these ultrasound measurements for kidney size 
are comparable with the voxel count method as measured on CT, and which volumetric 
equation is more accurate.
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MATERIALS AND METHODS
Donor selection
Between November 2013 and June 2014 all consecutive live kidney donors who were 
approved by a multidisciplinary team of surgeons, nephrologists and anesthesists were 
approached for ultrasound examination one day prior to donor nephrectomy. The choice 
for the side of donation is based on the principal that the donor should be left behind 
with his/her best kidney, which is generally determined by size. A pre-donation CT scan 
is performed to determine kidney size and the vascular anatomy. Donors were included 
when a pre-donation CT-scan of kidneys and ultrasonography of both ultrasonogra-
phists (US-1, SJ; US-2, HK) were present. In addition, both CT scan and ultrasonography 
acquired images should be conform study protocol and deemed of sufficient quality. 
The study protocol was approved by our local institutional review board (MEC-2012-
519) and written informed consent was obtained from all included study participants. 
All procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1964 and later versions.
Ultrasonography
The ultrasound examination was performed using a commercially available system 
(Hitachi HI VISION Avius®, with a EUP-C715 transducer; Hitachi Medical Systems, Zug, 
Switzerland). All ultrasound measurements included length, width, and thickness of the 
kidney performed independently by two trained ultrasonographists. The ultrasonog-
raphists, a surgeon and a physician - research fellow, were exclusively involved in live 
donor kidney imaging program since 2012. Both ultrasonographists were trained and 
supervised by an experienced radiologist (RD) with 10 years of clinical experience in 
abdominal imaging. The image quality was deemed adequate when clear margins of 
the kidney were visible to perform all measurements (Figs. 1a and 1b). Image quality was 
assessed by the supervising radiologist (RD). The maximum length of the kidney was 
measured in the coronal axis of the kidney with clear vision of the hilum (lengthus, Fig. 
1a). In this same image the maximum width was measured perpendicular to this plane 
at the renal hilum (widthus, Fig. 1a). The transducer was then turned 90° with clear vision 
of the hilum, including identification of the main renal artery and vein . The maximum 
thickness (medial-lateral diameter) of the kidney was measured from the lateral margin 
of the kidney to the renal sinus (thicknessus, Fig. 1b). All measurements were performed 
three times by each ultrasonographist. A mean difference of < 5 mm between similar 
mean measurements of both ultrasonographists was accepted as normal23-25 and only 
then defined as an accurate measurement. The kidney volume (volumeus) was calculated 
according to the commonly used volumetric ellipsoid equation (length in cm x width in 
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cm x thickness in cm x π/6), however, in previous studies this equation has demonstrated 
to underestimate the kidney volume19-22. Therefore, also a more accurate deemed volu-
metric ellipsoid equation was used with 0.674 as an correction factor instead of π/622.
Computed tomography
The CT scans were performed on a 128-multislice CT Systems (Siemens Healthcare, 
Erlangen, Germany). A standardized CT scan protocol was used in which a triple split 
contrast bolus was injected to achieve an arterial, venous and excretion phase in a single 
Figure 1. Measurement of the maximum length of the kidney (D1, A),   the maximum width (D2, A), 
the maximum thickness (D3, B) by the ultrasonagraphists, and CT volume by a specialized radiological 
assistant(C).
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scan acquisition. The maximum length of the kidney on the CT (lengthct) was determined 
by manual measurements on oblique multiplanar reformats parallel to the longitudinal 
axis of the kidney, reconstructed from 0.75 mm slices with 0.5 mm increment in 3D soft-
ware (AquariusNet, TeraRecon, Inc. Foster City, USA). All kidney volumes (volumect, Fig. 
1c) were measured by the voxel count method by a specialized radiological assistant. For 
the voxel count method, the axial CT images (0.75 mm thickness and 0.5 mm increment) 
were transferred to a dedicated CT volume measurement software (Syngo Volume Cal-
culation, Siemens Healthcare, Erlangen, Germany). On each axial image, contouring of 
the kidney was manually traced. A manual Hounsfield threshold adjusted to the density 
of the excretion contrast was set to also include the renal collecting system. The areas 
that were circumscribed by the manual contour on each slice were multiplied by the 
slice thickness and systematically summed to obtain kidney volume.
Statistical analysis
The inter-observer variability between both ultrasonographists and CT was determined 
by the Bland-Altman method26. The mean lengthus, widthus and thicknessus were calcu-
lated by the mean of the three measurements for each ultrasonographist. The lengthct as 
reported by the radiologist and volumect as calculated by the voxel count method were 
deemed as the accurate measurements. A paired sample T-test was used to determine 
the mean difference between CT and ultrasound measurements for length and volume. 
The relationship between CT and ultrasound was evaluated by linear regression analysis 
(Pearson correlation coefficient, r). All analyses were carried out using SPSS 22.0 for 
windows.
RESULTS
Fifty consecutive donors were approached to participate in this study and all met the in-
clusion criteria. Acquired images of all 100 kidneys were deemed adequate to guarantee 
accuracy of the measurements. Thus, no donors were excluded from this consecutive 
series. The mean age of the included population was 51.6 ± 15.7 years, with a mean BMI 
of 25.4 ± 4.8 kg/m2 (range 18.5-37.0), and 36% was male.
Accuracy of ultrasound measurements
In Table 1 the mean length and volume of CT, US-1 and US-2 of 100 kidneys are pre-
sented. The mean lengthct of the left kidney was 111.0 ± 10.3 mm and the mean lengthct 
of the right kidney was 108.7 ± 10.5 mm (P =0.284). The mean difference in lengthus 
between US-1 and US-2 for the left kidney was 1.5 ± 0.8 mm (P =0.062) and 2.0 ± 5.3 (P = 
0.011) mm for the right kidney. The inter-observer variability between CT, US-1 and US-2 
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for length is depicted in Bland-Altman plots in Figs. 2a-c. The mean difference between 
lengthct and lengthus for US-1 was 2.0± 7.1 mm (P = 0.057) for the left kidney and 2.1± 
7.3 mm (P = 0.041) for the right kidney, and for US-2 the mean difference was 0.4± 7.0 
mm (P = 0.678) for the left kidney and 0.2± 7.5 mm (P = 0.862) for the right kidney. There 
is a strong relation between lengthct and lengthus for both US-1 and US-2 as well as for 
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Figure 2. Bland-Altman plot of kidney length of ultrasonographist 1 versus ultrasonographist 2 (A), CT 
versus ultrasonographist 1 (B), and CT versus ultrasonographist 2 (C).
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the left (correlation coefficient 0.73 and 0.73 respectively) and right kidney (correlation 
coefficient 0.72 and 0.70 respectively) (P <0.001). In addition to lengthus, the volumeus is 
calculated by the widthus and thicknessus of the kidney. The mean difference in widthus 
of the left and right kidney between US-1 and US-2 was 0.9 ± 5.0 mm (P =0.203) and 
1.7 ± 6.7 mm (P = 0.082) respectively, and the mean difference in thicknessus of the left 
and right kidney between US-1 and US-2 was 3.0 ± 4.5 mm (P <0.001) and 1.5 ± 5.2 mm 
(P = 0.040) respectively. The mean differences for all measurements for both kidneys 
between US-1 and US-2 were ≤ 5 mm. Therefore, all measurements of both ultrasonog-
raphists were deemed accurate.
Table 1. Mean length and volume of CT, ultrasonographist 1, and ultrasonographist 2.
Mean
Length left kidney (mm)
CT 111.0 ± 10.3
ultrasonographist 1 112.9 ± 7.9
ultrasonographist 2 111.4 ± 7.8
Length right kidney (mm)
CT 108.7 ± 10.5
ultrasonographist 1 110.9 ± 8.5
ultrasonographist 2 108.9 ± 8.3
Volume left kidney (cm3)
CT 183.3 ± 43.4
Ellipsoid equation*
ultrasonographist 1 150.6 ± 30.1
ultrasonographist 2 155.3 ± 37.2
Adjusted volume equation†
ultrasonographist 1 193.7 ± 38.7
ultrasonographist 2 199.8 ± 47.9
Volume right kidney (cm3)
CT 177.4 ± 45.9
Ellipsoid equation*
ultrasonographist 1 146.6 ± 44.4
ultrasonographist 2 149.7 ± 39.8
Adjusted volume equation†
ultrasonographist 1 188.5 ± 57.2
ultrasonographist 2 192.6 ± 51.2
*mean lengthus (cm) x mean widthus (cm) x mean thicknessus (cm) x π/6
†mean lengthus (cm) x mean widthus (cm) x mean thicknessus (cm) x 0.674
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Difference in kidney volume
The mean volumect of the left kidney was 183.3 ± 43.4 cm3 and the mean volumect of 
the right kidney was 177.4 ± 45.9 cm3 (P =0.511). The inter-observer variability between 
volumect and volumeus for US-1 and US-2 for both volumetric ellipsoid equations are 
depicted in Bland-Altman plots in Figs. 3a-d. The mean difference between volumect and 
volumeus, calculated with the common ellipsoid equation, for the left and right kidney 
measured by US-1 was 32.7 ± 34.5 cm3 and 30.8 ± 22.7 cm3 respectively (P <0.001), and 
for US-2 28.0 ± 27.2 cm3 and 27.7 ± 26.8 cm3 respectively (P <0.001). The mean difference 
between volumect and volumeus, calculated with the adjusted ellipsoid equation, for the 
left and right kidney measured by US-1 was -10.4 ± 36.4 cm3 (P =0.048) and -11.1 ± 
28.1 cm3 (P =0.007) respectively, and for US-2 -16.5 ± 30.3 cm3 (P <0.001) and -15.2 ± 
30.1 cm3 (P =0.001) respectively. The common ellipsoid equation underestimated the 
kidney volume for US-1 with 16.9% and for US-2 with 14.8%, while the adjusted ellipsoid 
equation overestimated the kidney volume for US-1 with 6.8% and for US-2 with 9.5%. 
The relation between volumect and volumeus calculated with the adjusted volumetric 
ellipsoid equation is strong for both US-1 (correlation coefficient 0.76) and US-2 (correla-
tion coefficient 0.80) (both P <0.001). The calculated personalized correction factor for 
the left and right kidney for US-1 was 0.634 and 0.663, and for US-2 was 0.589 and 0.678.
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Figure 3. Bland-Altman plot of kidney volume of CT versus both ultrasonographists calculated with mean 
length x mean width x mean thickness x π/6 (A) and calculated with mean length x mean width x mean 
thickness x 0.674 (B).
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DISCUSSION
After live kidney donation adaptation of the remnant kidney is necessary to compensate 
for the loss of kidney function. Adaptation is associated with compensatory hypertrophy 
that can be monitored by measuring kidney volume27. We propose to use ultrasonogra-
phy as it offers a less expensive and less time-consuming imaging modality. In this study 
we demonstrated that: [1] kidney size measurements of length and volume performed 
by ultrasonography of both kidneys are comparable with CT measurements, and [2] that 
the adjusted volumetric ellipsoid equation by Zakhari et al.22 based on kidney ultrasound 
measurements of length, width and thickness demonstrated a more accurate volume 
estimation by a difference of less than 10% compared with the common volumetric el-
lipsoid equation18. This study has led to a feasible and accurate measurement for kidney 
volume. To our knowledge this is the first study to validate the adjusted volumetric 
ellipsoid equation by Zakhari et al.22 for clinical use.
Our study demonstrates a strong correlation between kidney length measurements on 
ultrasonography and CT. While the mean difference between both ultrasonographists 
was significantly different for lengthus of the right kidney and thicknessus of both kidneys, 
the difference of <5 mm is found acceptable between trained ultrasonographists23-25. 
These accurate ultrasound measurements have previously been confirmed by another 
study in 125 live kidney donors, which demonstrated a difference of 1.0-2.0 mm between 
all ultrasound and CT kidney length measurements28. In this study two measurements 
for CT length were used: the number of slices from top to bottom of the kidney times the 
thickness of the slices and length measurement in the coronal axis. While in our study 
CT length was measured on oblique multiplanar reformats parallel to the longitudinal 
axis of the kidney. In a study by Hwang et al.21 the measurements between ultrasound 
and CT in 139 donors were more accurate (1 mm) for the right kidney as compared with 
the left kidney (5 mm). In our study a similar mean difference for either the left or right 
kidney was demonstrated, which is found in the difference between the personalized 
correction factors for both kidneys. All-over, the accuracy of ultrasound measurements 
is demonstrated to be highly comparable to CT measurements.
We compared the commonly used volumetric ellipsoid equation (length x width x thick-
ness x π/6) with an adjusted volumetric ellipsoid equation in which 0.674 is used as 
an correction factor instead of 0.524 (π/6)22. Previous studies have demonstrated that 
the first equation underestimates the kidney volume compared with the voxel count 
method19-22, the latter is considered the gold standard for volume measurement. This 
underestimation was similar for our study with a total volume underestimation of 15-
17% on average for both kidneys, which is comparable with other studies (22-25%)19, 22. 
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The adjusted volumetric ellipsoid equation proved to be more accurate with an overes-
timation of 7-10%. Though, this difference was slightly higher compared to the 100% 
accuracy found in the study that proposed the adjusted equation, despite that we both 
included the renal collecting system in our volume measurements. This difference might 
be due to the fact that this study was done in a slightly larger sample size of 79 donors 
or that the adjusted equation is based on the measurement differences of another 
individual who solely performed all ultrasound measurements in this study22. However, 
the adjusted correction factor came close to the personalized correction factor for both 
US-1 and US-2.
Our study has several limitations worth mentioning. First, ultrasound measurements can 
be variable23-25, therefore only measurements performed by experienced ultrasonogra-
phists may be reliable. However, all our ultrasound measurements were independently 
performed by two ultrasonographists to achieve accuracy. Second, it should be noted 
that the sample size of 100 kidneys is relatively small for a validation study. However, due 
to the experienced ultrasonographists the variability of the ultrasound measurements 
of <5 mm difference has been accomplished. This strengthens the assumption that our 
US measurements are deemed accurate and reliable to be analysed. Last, this is the 
first study that has validated the Zakhari equation and an 100% accuracy is not accom-
plished. This indicates that a future study in a prospective cohort should be performed 
to validate the equation before it can be used for clinical purposes.
Pre-donation kidney volume is a significant predictor of volume increase in the remnant 
kidney, with lower pre-donation kidney volume being a significant predictor of delayed 
kidney function recovery6. The availability of a reliable technique to measure kidney 
volume pre-donation can enhance the kidney selection procedure prior to donation 
to maximize and maintain donor safety after donation. Furthermore, the degree of 
kidney function recovery can be reflected by measuring kidney volume after donation, 
which represents compensatory hyperfiltration. This study supports the feasibility and 
accuracy of a more cost-effective and approachable imaging modality; also to be used 
in less developed countries. Future studies should focus on the clinical implementation 
in a prospective cohort.
Ultrasound measurements for kidney size are comparable with CT measurements, allow-
ing the reliable use of ultrasound examination as imaging modality to determine kidney 
size during follow-up of live donors to monitor kidney adaptation. The use of different 
equations to calculate the volume was demonstrated to achieve the most accurate ul-
trasound volume estimate of the kidney. Therefore, ultrasonography, having low costs, 
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being non-invasive and showing comparable outcome as CT, seems the technique to be 
recommended for follow-up examination after live kidney donation.
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ABSTRACT
Worldwide, tens of thousands of healthy individuals participate in living kidney donation 
programs to help patients with end-stage renal disease. Recently, unfavourable results 
emerged from donor versus non-donors studies. We conducted a follow-up study of 761 
living kidney donors from The Netherlands who were propensity-score matched with 
1522 non-donors from two Western population-based cohort studies on age, gender, 
BMI, ethnicity, kidney function, blood pressure, pre-existing co-morbidity, smoking, al-
cohol use and highest education degree. Live kidney donations occurred between 1981 
through 2010 with follow-up until April 20th, 2016. The median follow-up time after do-
nation was 8.0 years. The primary outcome was kidney function as defined by creatinine 
level and eGFR at follow-up. One-year median eGFR was 59.0 ml/min/1.73 m2 (IQR 50.5-
68.6 ml/min/1.73 m2) and eGFR at follow-up was 59.9 ml/min/1.73 m2 (IQR 51.4-70.7 
ml/min/1.73 m2). Donors were found to have an increased serum creatinine of 26.03 
μmol/l (95%CI 24.17; 27.89), a decreased eGFR of 27.23 ml/min/1.73m2 (95%CI -28.61; 
-25.85), and eGFR decline of 31.70% (95%CI 29.94-33.46) as compared to non-donors. 
There was no difference in outcome between both groups for microalbuminuria, BMI, 
incidence of diabetes or cardiovascular events, and cardiovascular mortality. A lower risk 
of new-onset hypertension (OR 0.45, 95%CI 0.33; 0.62) was found among donors. The 
EQ-5D health-related quality of life was higher among donors, while the SF-12 physical 
and mental component scores were lower. In conclusion, one year after donation live 
donors have a reduced renal function, remaining stable without any kidney-related 
morbidity or mortality to at least eight years of follow-up. However, the decline in renal 
function may be further compromised when unforeseen conditions would develop that 
additionally affect renal function. Having knowledge of this risk, albeit small, donors 
should be well-informed by the medical team and offered lifelong follow-up to monitor 
the remnant renal function. 
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INTRODUCTION
Each year, nearly 5000 healthy individuals in Europe and 6000 in the United States 
participate in a living kidney donation program to help patients with end-stage renal 
disease (ESRD).1,2 Potential living donors are exhaustively screened by transplant pro-
fessionals, who select only those whose health will not be compromised by donation. 
The surgical donation procedure has been demonstrated to be safe with a low risk of 
peri-operative morbidity and a very low risk of procedure-related mortality.3,4 However, 
donors should be aware of the implications of donation in their future life. Compared 
to pre-donation levels, renal function initially decreases after donation5 but seems to 
remain stable with no further progression after more than a decade.6,7
Previously, it was assumed that donors have no increased risk of mortality,4,8-10 ESRD,8,11-13 
or gestational hypertension8,14 compared to non-donors. However, recent single-center 
and national registry studies on long-term follow-up outcomes comparing donors to 
non-donors have reported an increased risk of mortality,15 ESRD,15-17 gestational hyper-
tension, and pre-eclampsia18 among donors. These conflicting results are mainly due to 
the incomparability of donors and non-donors because of limitations in the included 
study population and analysis.19 Live kidney donors represent a screened and selected 
cohort of the population that is inherently healthier than the general population, which 
jeopardizes the comparability of donors and non-donors when studying outcomes. 
Furthermore, low absolute risk among donors creates uncertainty in estimates when 
adjusting for potential confounders.19 Strengths of recent studies compared to previous 
studies are the extended time for follow-up after donation, large sample sizes, and bet-
ter analysis,15-18 increasing the reliability of estimating potential risks for living kidney 
donors in the long-term. 
Determining the long-term impact of living donation is essential and criteria are needed 
to identify the donors at risk in the long-term. In the present study, we aim to evaluate 
the long-term consequences for live kidney donors compared to matched non-donors 
regarding kidney function, including hypertension, diabetes mellitus, cardiovascular 
events, survival, and quality of life. 
METHODS
Study design
We performed a propensity-score matched follow-up study using individual level donor 
data from Erasmus University Medical Center, and comparison data from two popula-
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tion-based follow-up studies. All eligible donors were invited for an extensive study visit 
that included self-reported medical history, and an interview-based questionnaire on 
quality of life, supplementary to their annual physical examination and laboratory tests. 
The study visits were conducted between August 19, 2013, and December 31, 2014. 
To increase the response among donors, the visits were also conducted at another 
academic university medical center and one district hospital located in different prov-
inces of the Netherlands. Donors were included in the study if they were alive during 
the inclusion period, lived in the Netherlands, and visited one of the study hospitals 
or filled out self-report forms. All questionnaire-related interviews were conducted by 
three investigators. Non-participants were asked to fill out self-report forms on their 
medical history and quality of life and permission requested for access to their medical 
records in order to analyze potential selection bias. The conduct and reporting of the 
study followed guidelines for observational studies20 (Supplemental Table S1). The study 
was designed by the authors21 and approval obtained by the medical ethics committee 
of Erasmus University Medical Center, Rotterdam, the Netherlands (MEC-2012-519). 
Informed consent was obtained from all study participants.
Data sources
All data were obtained from self-reporting, interview-based questionnaires, physical 
examination, and laboratory tests. To ensure the accuracy and completeness of the 
donor data, we manually reviewed the pre-donation and annual follow-up medical 
records in the hospital’s electronic patient database. We also obtained information from 
two linked databases containing the municipal administration records on vital status 
and demographic characteristics for all inhabitants. Outcome data were complete for all 
variables in this study except for quality of life scores among non-donors.  
Population
Donors
We included all individuals who donated a kidney from 1981 through 2010 at the 
Department of Surgery of Erasmus University Medical Center or who had their full 
medical work-up performed at the Erasmus University Medical Center prior to donation 
but donated at another transplant center because of their participation in the national 
kidney exchange transplant program.22 We identified 1092 study-eligible donors (See 
Supplemental Figure S1 for an overview of the number of donations per year).
Non-donors
Inhabitants of Western Europe have similar donation and transplantation legislation, 
lifestyles, and healthcare systems and access.23-25 Therefore, non-donors were selected 
from the Study of Health in Pomerania (SHIP)26 in Germany, a population-based cohort 
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study with participants aged 20-70 years, and the Rotterdam Study27 in the Netherlands, 
a population-based cohort study with participants aged 45 years and older. SHIP is a 
population-based cohort study initiated in 1997 among inhabitants of West Pomerania 
in the north-east of Germany. Two main objectives of this study were first to assess prev-
alence and incidence of common risk factors, subclinical disorders and clinical diseases, 
and second to investigate the complex associations amongst these. The Rotterdam 
Study is a prospective cohort study that started in 1990 in Ommoord, a district of the 
city of Rotterdam, the Netherlands. The study targets cardiovascular, endocrine, hepatic, 
neurological, ophthalmic, psychiatric and respiratory diseases. Both population-based 
studies were selected to cover the whole age range of our donors. Participants from 
the SHIP-0 cohort who enrolled between 1997 and 2001 (n=4308) were selected on 
sufficient follow-up time. Participants from the Rotterdam Study II and III cohorts who 
enrolled between 2000 and 2001 or 2006 and 2008, respectively (n=6943), were selected 
to ensure the presence of studied outcomes compared to cohort I. Data were taken from 
the latest follow-up examinations of both cohorts, 2012 for the SHIP and 2015 for the 
Rotterdam Study. 
Restriction, multiple imputation, and matching were used to select a cohort of non-
donors that was just as healthy as the donors (Supplemental Methods). We restricted the 
sample of all Rotterdam Study and SHIP participants (n=11,251) to eligible non-donors 
without identified contraindications for donation (n= 9270) at the time of enrollment 
in the population-based cohort studies, including pre-existing diabetes, an estimated 
glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 (defined by blood or urine analy-
sis), and BMI > 40 kg/m2. To account for the fact that the data on covariates at baseline 
were not complete for all subjects, a multiple imputation approach was utilized to im-
pute missing covariate values based on the method of chained equations.28 Using this 
procedure, 20 complete data sets were created. For each imputed data set, non-donors 
were matched to donors with replacement using propensity score matching.29,30 Bal-
ance between the donor and non-donor groups was checked with summary measures 
of Q-Q plots comparing the covariates in the matched groups.31 Initially, a 4:1 match was 
targeted,21 but the ratio was reduced to 2:1 to strive for optimal balance. Matching was 
based on baseline characteristics of age (years), gender, year of donation/enrollment 
in the population-based cohort study, weight (kg), height (cm), ethnicity, eGFR (ml/
min/1.73 m2), systolic and diastolic blood pressure (mmHg), pre-existing hypertension, 
pre-existing cardiovascular events, serum glucose level (mmol/l), current smoking, 
alcohol use, and education level. 
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Study outcomes
All study subjects were followed until death, emigration out of the country, or the 
end of the examination period (April 20, 2016, for donors, and December 31, 2015, for 
non-donors). The primary outcome was defined as kidney function based on serum 
creatinine (μmol/l) and eGFR (ml/min/1.73 m2; calculated using the CKD-EPI formula32), 
and measured at baseline, one year after donation (donors only), and at long term 
follow-up32. Secondary outcomes were incidence of hypertension (defined as use of 
antihypertensive medication, systolic blood pressure ≥ 140 mmHg, or diastolic blood 
pressure ≥ 90 mmHg), incidence of diabetes (defined as use of antidiabetic medication 
or glucose ≥ 7 with diet), BMI (kg/m2), incidence of cardiovascular events (defined as 
myocardial infarction, percutaneous coronary intervention, coronary artery bypass 
surgery, or cerebral vascular accident), cardiovascular mortality (defined as death by 
cardiovascular event), mortality (censor date April 20, 2016, for donors; December 31, 
2012 for the SHIP; and December 31, 2015, for the Rotterdam Study), and quality of life 
measured by ShortForm-12 (SF-12)33 and EuroQoL (EQ-5D)34. The Short Form health 
questionnaire is a validated and commonly used tool to measure health related quality 
of life ranging from a score between 0-100. It contains questions on physical perfor-
mance and well-being, and mental functioning and emotional well-being, resulting in 
the physical (PCS) and mental component score (MCS) respectively. The EQ-5D records 
quality of life in five dimensions: mobility, self-care, daily activities, pain or discomfort, 
and anxiety/depression. The responses on the five dimensions combine to a score ac-
cording to Dutch tariff35 between -0.59 (worst imaginable health state) and 1.00 (best 
imaginable health state).
Statistical analysis
Our approach to data-analysis was as follows. Baseline characteristics were compared 
using the Kruskal-Wallis test for continuous variables and the Fisher’s exact test for 
dichotomous variables. 
All analyses were performed for each of the completed data sets and the results from the 
analysis of each imputed data combined using Rubin’s formulas.36 The analyses of continu-
ous outcomes were based on linear regression and the analyses of dichotomous outcomes 
on logistic regression. For each regression analysis we tested for differences between 
donors and non-donors while also correcting for the covariates age, gender, start year 
(date of donation or enrollment in population-based study), education level, pre-existing 
hypertension, baseline serum creatinine, and baseline eGFR, as well as weight, height, 
alcohol use, and smoking status at follow-up. To evaluate potential effect modification, 
interactions were tested by age, gender, and follow-up duration in the final multivariate 
model of kidney function. The results have not been corrected for multiple testing.
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PRELIMINARY RESULTS
Characteristics of the study participants
Between 1981 and 2011, a total of 1092 live kidney donations were performed at our 
center and all donors were eligible for inclusion. A total of 761 donors were matched 
with non-donors, including 705 who visited the outpatient clinic (Figure 1). The donors 
comprised 429 living-related (54.1%) and 332 living-unrelated (45.9%) live kidney dona-
tions. The median follow-up time for donors was 8.0 (5.1-11.9) years. Non-donors from 
the Rotterdam Study and SHIP were included; a total of 11,251 individuals participated in 
these population-based cohort studies. After restriction, 9270 non-donors were eligible 
for 2:1 matching, resulting in 1522 non-donors being included in the study, 54.1% from 
the Rotterdam Study and 45.9% from SHIP. The median follow-up time for non-donors 
was 7.0 (5.4-10.9) years. Age, baseline systolic blood pressure, ethnicity, and education 
were signifi cantly diff erent between donors and non-donors (Table 1), but diff erences 
were relatively small.
Figure 1. Flowchart of inclusion in the live kidney donor process
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Study outcomes
In the donor population, baseline eGFR was 92.6 ml/min/1.73 m2 (IQR 79.8-103.8 ml/
min/1.73 m2), one-year eGFR was 59.0 ml/min/1.73 m2 (IQR 50.5-68.6 ml/min/1.73 m2), 
and median eGFR at follow-up after 8 years 59.9 ml/min/1.73 m2 (IQR 51.4-70.7 ml/
min/1.73 m2) (Figure 2). The creatinine level for donors was 77.0 μmol/l (IQR 68.0-87.0 
μmol/l) at baseline, 106.0 μmol/l (IQR 93.0-121.0 μmol/l) at one-year and 100.0 μmol/l 
(IQR 87.5-114.0) μmol/l at 8-year follow-up. The primary outcomes for renal function 
were all significantly inferior for donors compared to non-donors; serum creatinine was 
significantly higher (+26.03 μmol/l (95% CI 24.17; 27.89)) and the eGFR significantly lower 
(-27.23 ml/min/1.73 m2 (95% CI -28.61; -25.85)). The eGFR declined 31.70 percent (95% CI 
29.94; 33.46) more among donors than non-donors (all p<0.001, Table 2). Sixteen donors 
(2.4%) and 10 non-donors (1.2%) developed microalbuminuria (p=0.093). These donors 
had a median eGFR of 57.9 ml/min/1.73 m2 (IQR 47.7-68.2 ml/min/1.73 m2) and median 
creatinine of 99.5 μmol/l (IQR 86.1-112.9 μmol/l) at follow-up. Two donors (0.3%) devel-
Table 1. Baseline characteristics of included live kidney donors at the time of donation and matched non-
donors at the time of enrolment in population based cohort studies
Characteristics Donors (n=761) Nondonors (n=1522) P-value
median (IQR)/N (%) median (IQR)/N (%)
age (years) 51.9 (42.8-60.1) 51.0 (37.8-57.9) p<0.001
gender (male) 318 (41.8) 636 (41.8) p=1.000
ethnicity (white) 681 (89.5) 1434 (94.2) p=0.001
BMI (kg/m2) 25.9 (23.4-28.4) 25.5 (22.9-28.2) p=0.176
systolic blood pressure (mmHg) 130.0 (120.0-140.0) 125.5 (114.0-142.0) p=0.010
diastolic blood pressure (mmHg) 79.0 (70.0-85.0) 77.0 (70.0-85.0) p=0.964
eGFR (ml/min/1.73m2) 92.6 (79.8-103.8) 90.0 (78.9-102.3) p=0.160
serum glucose (mmol/l) 4.9 (4.3-5.4) 5.0 (4.7-5.4) p=0.778
pre-existing hypertension* 299 (39.3) 592 (38.9) p=0.891
pre-existing cardiovascular disease 13 (1.7) 28 (1.8) p=0.956
smoking 400 (52.6) 867 (57.0) p=0.051
alcohol use p=0.560
never/rare 340 (44.7) 703 (46.2)
≤7 glasses/week 294 (38.6) 553 (36.3)
>7 glasses/week 127 (16.7) 266 (17.5)
education degree p=0.011
primary 86 (11.3) 159 (10.4)
secondary 418 (54.9) 782 (51.4)
tertiary 257 (33.8) 581 (38.2)
* defined as use of antihypertensive medication, systolic blood pressure ≥140 mmHg or diastolic blood pressure 
≥90 mmHg
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oped ESRD: one female donor, 60 years of age and 28 years after donating her kidney 
to her son and one male donor, 46 years of age and 12 years after donation to his sister. 
In the first patient the renal failure was caused by the use of diuretics to treat ascites 
due to alcoholic liver cirrhosis. Being on dialysis this patient passed away at the age of 
66 due to progression of her liver disease. The second patient developed hypertensive 
nephropathy, proteinuria, and subsequent renal failure, caused by nephrosclerosis as 
demonstrated by renal biopsy. This donor had withdrawn himself from annual visits to 
the outpatient clinic for several years before renal failure was diagnosed. He received a 
kidney transplant from his son and his current eGFR at follow-up was 76.3 ml/min/1.73 
m2 with a creatinine level of 99.0 μmol/l.
Secondary outcomes showed no significant differencesbetween donors and non-
donors for BMI (0.02, (95%CI -0.04; 0.07), incidence of diabetes (OR 1.14, 95%CI 0.71; 
1.84), cardiovascular events (OR 1.06, 95%CI 0.64; 1.74), and cardiovascular mortality (OR 
0.13, 95%CI 0.01; 1.24). A significantly lower risk of developing new-onset hypertension 
(OR 0.45, 95% CI 0.33; 0.62) and overall mortality (OR 0.13, 95% CI 0.06; 0.27) was found 
among donors. Nine donors (1.2%) passed away after visiting one of the study hospitals 
prior to their death, one of whom died of a cardiovascular event. Of the entire 1981-2011 
donor population (n=1092), 80 donors passed away: 38 of a malignant disease and 15 of 
a cardiovascular event. 
The health-related quality of life score was significantly higher among donors with 0.06 
higher score for EQ-5D  (95% CI 0.05; 0.08 on a scale of -0.59 to 1.00. The SF-12 physical 
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and mental component score were both significantly lower among donors: -1.36 (95% CI 
-2.38; -0.33) and -4.61 (95% CI -5.75; -3.47), respectively, on a scale of 0-100.
DISCUSSION 
In this European study of live kidney donors and matched non-donors from the gen-
eral population, we demonstrated a reduction in renal function in the first year after 
donation, thereafter stabilizing at least until the moment of measurement after 8 years 
of follow-up; no effect of reduced renal function was found on the secondary health-
related outcomes.
Notably, the eGFR and creatinine levels among donors were decreased at follow-up as 
compared to the general population (Table 2). This change in renal function may be at-
tributed to the donation procedure, since the eGFR declined in the first year after dona-
tion and remained stable thereafter. Compared to previous studies19 a main strength of 
our study lies in the quantification of renal function with repeated serum measurements 
Table 2. Long-term outcomes of live kidney donors compared with matched non-donors after an overall 
median follow-up of 7.3 years
Outcome Effect estimate* 95% CI P-value
Primary outcomes
Serum creatinine (μmol/l) 26.03 24.17; 27.89 p<0.001
eGFR (ml/min/1.73m2) -27.23 -28.61; -25.85 p<0.001
eGFR decline (%) -31.70 -33.46; -29.94 p<0.001
Secondary outcomes
BMI (kg/m2) 0.02 -0.04; 0.07 p=0.583
New-onset diabetes 1.14 0.71; 1.84 p=0.585
New-onset hypertension** 0.45 0.33; 0.62 p<0.001
Cardiovascular event 1.06 0.64; 1.74 p=0.823
Cardiovascular mortality 0.13 0.01; 1.24 p=0.077
Overall mortality 0.13 0.06; 0.27 p<0.001
SF-12 physical component score -1.36 -2.38; -0.33 p=0.010
SF-12 mental component score -4.61 -5.75; -3.47 p<0.001
EQ-5D 0.06 0.05; 0.08 p<0.001
*β for continuous outcome, odds ratio for dichotomous outcome
** Study participants with pre-existent hypertension are excluded from analysis. Defined as use of antihy-
pertensive medication, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg
Model adjusted for: age, gender, start year (date of donation or enrolment in population-based study), 
education degree level, pre-existing hypertension, baseline serum creatinine, baseline eGFR, and weight, 
height, alcohol use, and smoking status at follow-up.
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and additional urine analyses over time. In a study by Ibrahim et al. the outcome for eGFR 
and creatinine among donors were similar to our findings. The decline in eGFR among 
donors in our study was also similar to that reported in previous studies.6,37 However, 
the microalbuminuria percentage in the study by Ibrahim et al. was found to be higher 
as compared to our findings.8 In our study only 16 donors (2.4%) had microalbuminuria 
with a median eGFR of almost 60 ml/min/1.73 m2, indicating that none of the donors 
were currently at risk for ESRD. The two donors that did develop ESRD did so because of 
reasons unrelated to the donation. 
A strength of our study is that we collected, in addition to national registry data as used 
in other studies,15,16 individual donor and non-donor level data on medical conditions, 
physical examinations, laboratory tests with quantification of renal function, medication 
use, all manually verified by medical records and with minimal missing data (<8%). Fur-
thermore, as compared to previous studies the current study design was optimized for 
donor and non-donor comparison by matching on more baseline health characteristics, 
including renal function and comorbidity, adjusting for current lifestyle factors includ-
ing alcohol use and smoking, and performing propensity score matching suitable for 
observational data which balances both groups on a large number of covariates without 
losing a large number of observations4,8-10,15,16,18,19,38. All donors and non-donors had ac-
cess to similar health care services.
Our study has certain limitations. First, data on the use of antihypertensive medication 
were not available from our data sources. Second, blood pressure was measured once 
for donors and average of 2-3 measurements for non-donors. Third, for SHIP partici-
pants, percutaneous coronary intervention and coronary artery bypass surgery were not 
included as cardiovascular events. In addition, EQ-5D scores were only available in the 
Rotterdam Study and SF-12 scores were only available in the SHIP. Finally, the eGFR is 
only an estimation of the renal function. A GFR from a 24-h urine sample would be more 
accurate. However, the eGFR CKD-EPI formula32 is a common clinically and internation-
ally used equation. Furthermore, eGFR is common in population level studies due to 
logistic difficulties in 24-h urine collection.  
Several studies on live kidney donation have used a similar comparison design with 
matched non-donors and reported similar outcomes in overall mortality and cardiovas-
cular events.4,8,10 However, others have reported contradicting results 15,38. These contra-
dictories can be explained by differences in the methodological design, questioning the 
comparability of donors and non-donors and the reliability of the results.19 Live kidney 
donors are healthy individuals and submitting them to a surgical procedure stretches 
the Hippocratic oath taken by physicians. Therefore, prior to donation, a well-considered 
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decision has to be made regarding the surgical suitability and the risk estimation for 
donation.  By extensively screening donors the healthiest individuals are selected, which 
may impede the comparability with non-donors from the general population. Compar-
ing donors to the general background population can underestimate risks additional 
to donation.9 Matching donors to selective non-donors with similar baseline health 
status can overcome this impediment. It is important that comprehensive data becomes 
available for this process to strive for an equal health status between donors and non-
donors, allowing proper analysis of the donation procedure on risk factors. As compared 
to recent literature we have added these factors to our study design by matching and 
adjusting for multiple health characteristics. Thus, this study strives to be representative 
donors and non-donors in Western populations. The next step would be to predict the 
attributable risk for individual donors prior to donation.17 This approach would help to 
identify those donors that may be at risk for reduction of renal function,39 either related 
to future co-morbidity or medication affecting renal function. 
In conclusion, live donors have reduced renal function compared to non-donors, oc-
curring in the first year after donation and stabilizing thereafter for at least 8 years with 
equal outcome for morbidity or mortality as compared to non-donors.  No differences 
were found in the risk on hypertension or cardiovascular disease and mortality. However, 
the substantial decline in renal function may be further compromised when unforeseen 
circumstances affect renal function later in life. With the knowledge of this risk, albeit 
small, donors should be well-informed before donation and be offered lifelong follow-
up thereafter. By monitoring the remnant renal function, donors at risk may be identi-
fied in early stage and adequate treatment may be offered. We consider this approach a 
prerequisite to legitimize a living kidney donor program.
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SUPPLEMENTAL METHODS 
Restriction, multiple imputation, and matching
A total of 11,251 participants from the SHIP (n=4308) and the Rotterdam Study (n=6943) 
were eligible as non-donors. After restricting participants (total n=1981; SHIP n= 816, 
Rotterdam Study n=1165) with pre-existing diabetes, an (e)GFR < 60 ml/min/1.73 m2, 
and BMI > 40 kg/m2, a total of 9270 participants were identified (SHIP n= 3492, Rot-
terdam Study n= 5778). 
Due to missing baseline data on BMI (5.9%), ethnicity (2.7%), eGFR (7.8%), systolic (5.5%) 
and diastolic (5.5%) blood pressure, pre-existing hypertension (4.6%), pre-existing car-
diovascular events (0.2%), serum glucose level (7.5%), current smoking (0.5%), alcohol 
use (3.5%), and education level (2.6%), multiple imputations based on the method of 
chained equations28 was performed for 1092 donors, 3492 participants from SHIP, and 
5778 participants from the Rotterdam Study. 
All 761 donors included in the study were matched based on propensity scores to two 
non-donors from among the 9270 participants with replacement. Matching covariates 
were age, gender, year of donation/enrollment in the population-based cohort study, 
BMI, ethnicity, eGFR, systolic and diastolic blood pressure, pre-existing hypertension, 
pre-existing cardiovascular events, serum glucose level, current smoking, alcohol use, 
and education level. Matching was performed using the optimal matching algorithm 
implemented in the R package as optmatch.30 This algorithm finds the best match based 
on all variables together. On average (over the 20 multiple imputed data sets), 103 non-
donors were used more than once to match with a donor.
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Supplemental Table S1. STROBE Statement—Checklist of items that should be included in reports of co-
hort studies
Item no. Recommendation
 Title and abstract 1 (a)  Indicate the study’s design with a commonly used term in the title or 
the abstract.
(b)  Provide an informative and balanced summary of what was done and 
what was found.
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported.
Objectives 3 State specific objectives, including any pre-specified hypotheses.
Methods
Study design 4 Present key elements of study design early in the paper.
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection.
Participants 6 (a)  Give the eligibility criteria and the sources and methods of selecting 
participants. Describe follow-up methods.
(b)  For matched studies, give matching criteria and number of exposed 
and unexposed.
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 
and effect modifiers. Give diagnostic criteria if applicable.
Data sources/ 
measurement
8* For each variable of interest, give sources of data and details of the methods 
of assessment (measurement). Describe the comparability of assessment 
methods if there is more than one group.
Bias 9 Describe any efforts to address potential sources of bias.
Study size 10 Explain how the study size was arrived at.
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why.
Statistical methods 12 (a)  Describe all statistical methods, including those used to control for 
confounding.
(b)  Describe any methods used to examine subgroups and interactions.
(c)  Explain how missing data were addressed.
(d)  If applicable, explain how loss to follow-up was addressed.
(e)  Describe any sensitivity analyses.
Results
Participants 13* (a)  Report number of individuals at each stage of the study: e.g., potentially 
eligible, examined for eligibility, confirmed eligible, included in the 
study, completing follow-up, and analyzed.
(b)  Give reasons for non-participation at each stage.
(c)  Consider use of a flow diagram.
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Supplemental Table S1. STROBE Statement—Checklist of items that should be included in reports of co-
hort studies (continued)
Item no. Recommendation
Descriptive data 14* (a)  Give characteristics of study participants (e.g., demographic, clinical, 
social) and information on exposure and potential confounders.
(b)  Indicate the number of participants with missing data for each variable 
of interest.
(c)  Summarize follow-up time (e.g., average and total amount).
Outcome data 15* Report number of outcome events or summary measures over time.
Main results 16 (a)  Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (e.g., 95% confidence interval). Clearly 
indicate which confounders were adjusted for and why they were 
included.
(b)  Report category boundaries when continuous variables were 
categorized.
(c)  If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period.
Other analyses 17 Report other analyses done: e.g., analyses of subgroups and interactions, 
and sensitivity analyses.
Discussion
Key results 18 Summarize key results with reference to study objectives.
Limitations 19 Discuss study limitations taking into account sources of potential bias or 
imprecision. Discuss both the direction and magnitude of any potential bias.
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence.
Generalizability 21 Discuss the generalizability (external validity) of the study results.
Other information
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is based.
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Live kidney donation has become a wide accepted and implemented renal replacement 
therapy with the best prognosis and patient and graft survival as compared to dialysis. 
Nowadays, it is no longer indispensable in the treatment for patients with end-stage 
renal disease. However, the donation program is dependent on healthy individuals who 
are willing to undergo major surgery to improve the well-being of another individual. 
Therefore, the living donation program can only be legitimized when minimal discom-
fort during the procedure and maximum lifelong safety after donation can be guaran-
teed. In the past decades surgical techniques have been optimized and minimal invasive 
procedures have become the standard of care, leading to minimized discomfort and 
faster recovery compared to open procedures. Prior to donation potential donors are 
exhaustively screened to evaluate their medical suitability according to the Amsterdam 
forum donor eligibility acceptance criteria, established in 2004. These criteria evaluate 
potential donors with low risk for kidney-related morbidity or end-stage renal disease. 
However, due to the higher demand of organ donors, these criteria have been extended 
gradually and older donors and donors with minor comorbidities have become ac-
cepted for donation in the past decade. To date, short-term studies show excellent 
results regarding kidney function, mortality and morbidity but it should be noted that 
these studies do not include significant numbers of donors with extended eligibility 
acceptance criteria. In addition, focus on risk factors following live kidney donation has 
shifted from short-term to long-term evaluation, and from analysis of single center or 
national donor cohort studies to studies comparing donors with selected matched non-
donors. Currently, knowledge is gathered to evaluate the lifelong health implications 
after living kidney donation.
EXISTING LITERATURE
Live kidney donation has started in the 1960s and has been implemented worldwide. 
Previous long-term studies demonstrated excellent results in favour of the donor, but 
recently discussion started on the long-term safety as studies were published suggest-
ing unfavourable outcomes following donation compared with a cohort of matched 
non-donors (Chapter 2). These studies comprised large donor sample sizes compared 
with a matched cohort of non-donors from the general population. The baseline data 
for donors were derived from prospective national donor registries and for non-donors 
from population-based cohort studies or national health registries. The absolute risks 
for donors were demonstrated to be very low, while the adjusted risk analysis showed 
an increased risk additional to donation. Several explanations for these increased risks 
additional to donation have been suggested, most of them based on methodological 
design of studies; leading to bias and overestimation of risk. Donors are a medically 
112 Chapter 7
screened selection of the general population and thus inherently healthier. Therefore, 
donors should be matched to non-donors based on similar baseline conditions. Further-
more, the selection of donors and the comparison cohort of matched non-donors should 
maintain similar criteria. In recent studies, stricter exclusion criteria for non-donors led 
to a healthier non-donor cohort. In addition, after donation donors might be more 
aware of their health, being monitored on a regular base, and medical conditions could 
therefore be registered earlier in these donors than in non-donors. This might lead to a 
higher number of donors with a new event in their medical history as compared with 
non-donors and bias study outcome. As the absolute risks on morbidity after kidney 
donation are low, it’s a challenge to define proper statistical analyses when trying to 
correct for confounding. Indeed, study design as such might lead to overadjusting for 
confounders and less reliable results. On the other hand, strong points of recent studies 
are the large sample sizes and longer follow-up. Future studies have to take the limita-
tions and strong points in mind when trying to answer the question on long-term safety 
of living kidney donation. When consulting potential donors the results of these studies 
should be taken in consideration with their limitations in mind.
LONG-TERM FOLLOW-UP EVALUATION
Living kidney donors are selected according to the Amsterdam forum donor eligibil-
ity acceptance criteria and probably will have a lower risk for cardiovascular disease, 
kidney-related morbidity or end-stage renal disease during follow-up. However, life style 
may influence and dominate outcome and donors may have a disadvantage as renal 
reserve to compensate for loss of kidney function is reduced due to donation. As the 
development of cardiovascular disease or chronic kidney disease takes years, short-term 
follow-up studies might underreport these consequences. Therefore, long-term studies 
are necessary to define the safety boundaries of live kidney donation.
We have studied long-term outcomes ten and five years after donation in two prospec-
tive cohorts of 100 and 190 donors included between 2001-2004 and 2009-2011 respec-
tively (Chapters 3 and 4), in randomized controlled trials comparing different surgical 
techniques. In the first study ten years after donation next to kidney function additional 
analyses were performed on (new-onset) hypertension, quality of life and survival. In the 
second study more donors with extended eligibility acceptance criteria were included, 
proteinuria and microalbuminuria were measured, kidney function decline registered, 
and kidney function compared to a selection of non-donors derived from the general 
population. In addition, longitudinal analyses were added on kidney function and qual-
ity of life to evaluate the effect of extended eligibility acceptance criteria, such as higher 
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age, higher BMI and the prevalence or incidence of hypertension, and to evaluate if 
donors were at risk for a progressive decline in kidney function.
Both studies demonstrated that kidney function initially declined after donation as 
might be expected, restored somewhat in the months thereafter and stabilized at a 
level identical to the one-year follow up measurement. Thereafter, the kidney function 
remained stable up to over ten years. The overall eGFR decline was 14% after ten years in 
the first cohort and 34% after five years in the second cohort. The additional comparison 
in the second study demonstrated that donors had a kidney function within the lower 
range of matched age-categories of a population-based reference group. Furthermore, 
there was no different outcome in eGFR or eGFR decline in donors with extended 
eligibility criteria. In addition, the second study demonstrated that no proteinuria or 
microalbuminuria was observed in any of the donors, not even in donors with an eGFR 
<60 ml/min/1.73 m2. Donors with an eGFR <60 ml/min/1.73m2 were significantly older at 
the time of donation and had a lower pre-donation kidney function than donors with an 
eGFR ≥60 ml/min/1.73m2. In addition, the second study demonstrated that their eGFR 
decline was higher. Also, in longitudinal analyses of this study age and gender were as-
sociated with a decline in eGFR, whereas male gender was associated with a progressive 
decline in kidney function. None of the donors developed end-stage renal disease or 
required renal replacement therapy.
Donors who developed hypertension were significantly older at time of donation, with 
a higher BMI, and lower eGFR before donation when compared to donors who did not 
develop hypertension. Furthermore, the second study demonstrated that there were 
more donors with an eGFR <60 ml/min/1.73m2 with new-onset hypertension compared 
to non-hypertensive donors. In addition, the second study found that donors with a 
pre-existent or new-onset hypertension did not have a progressive decline in kidney 
function. The kidney function of pre-existent hypertensive donors was not significantly 
different compared to non-hypertensive donors, while that of new-onset hypertensive 
donors was. However, the decline in kidney function of all these donors was not signifi-
cantly different.
The quality of life scores of both studies were better or similar compared to general 
population scores, except for the mental component score in the second study. This 
was likely related to other life events than the donation. All quality of life scores signifi-
cantly decreased at follow-up, as might be expected from data derived from the general 
population. The overall decrease in all measures overtime is a phenomenon that has also 
been observed in the general population. In longitudinal analyses age and gender were 
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associated with a decline in quality of life, which are known factors. Donors who have 
passed away during follow-up died due to non-donation related causes.
To increase the sample size of our studies and evaluate risk additional to donation by 
comparing donors to non-donors, we designed a comparitive follow-up study with 
individual level donor data matched with non-donors from two population-based pro-
spective cohort studies to cover the whole age range of our donors (Chapter 6). We have 
incorporated the limitations of previous studies by selecting the entire donor cohort 
from 1981-2010 to evaluate outcomes on the long-term, selecting more and similar 
covariates for matching, and adjusting for more follow-up covariates during the analysis 
to enhance the comparability of donors to non-donors. This study comprised 761 in-
cluded donors and 1522 non-donors from the general population for analysis. Our study 
demonstrated that live donors have reduced renal function compared to non-donors, 
occurring in the first year after donation and stabilizing thereafter for at least 8 years 
with equal outcome for morbidity or mortality as compared to non-donors.  No differ-
ences were found in the risk on hypertension or cardiovascular disease and mortality.
CONCLUSION AND FUTURE PERSPECTIVES
In this thesis we have evaluated the long-term impact of living donation by review-
ing the recent literature and analysing the current donor eligibility criteria. We have 
pointed out the limitations of recent studies on long-term outcome after live kidney 
donation that could have led to a potential overestimation of risk additional to dona-
tion. Key problems remain such as that donors are a pre-screened healthy selection 
of the general population, making it difficult to find an equal healthy unscreened 
comparison group. Studies should select the entire donor cohort to evaluate long-term 
outcomes, maintain similar selection criteria for donors and non-donors, match on 
baseline covariates to enhance comparability, and adjust for follow-up covariates to 
correct for lifestyle factors. We have evaluated the current donor eligibility acceptance 
criteria of our own center by performing a comparative follow-up cohort study in which 
donors were compared to matched non-donors and aforementioned adjustments 
have been implemented in the study design. The results demonstrated that one year 
after donation live kidney donors have a reduced renal function, remaining stable 
without any kidney-related morbidity or mortality to at least eight years of follow-
up.  However, the substantial decline in renal function may be further compromised 
when unforeseen circumstances affect renal function later in life. With the knowledge 
of this risk, albeit small, donors should be well-informed before donation and be of-
fered lifelong follow-up thereafter. By monitoring the remnant renal function, donors 
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at risk may be identified in early stage and adequate treatment may be offered. We 
consider this approach a prerequisite to legitimize a living kidney donor program. 
Future studies are indicated to consult potential donors on their specific additional risk 
for a progressive loss of renal function after kidney donation. Ideally, the next step would 
be to predict the attributable risk for future donors prior to donation by uncovering risk 
estimates for long-term outcomes and how these risks would change if an individual 
becomes a live kidney donor. It is of utmost importance to further evaluate the possible 
attributable risk for donors prior to donation to maintain lifelong donor safety.
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SUMMARY
Chapter 1 provides a general introduction with an overview of the development of live 
kidney donation over the years. The increasing incidence of end-stage renal disease 
(ESRD) and the persistent organ shortage warranted the need for new developments 
in renal replacement therapy in the late 1980s and 1990s. Studies demonstrated that 
renal transplantation offers the best prognosis and long-term benefit for patients with 
ESRD compared to other renal replacement therapies. The gap between deceased 
organ demand and supply increased the number of live kidney donations. Significant 
benefits for recipients from live kidney donor transplantation as compared to deceased 
organ transplantation were demonstrated in several studies: superior organ quality, 
increased graft survival and the possibility of pre-emptive transplantation. Furthermore, 
the surgical technique improved and it was demonstrated in several studies that live 
donor nephrectomy is a safe surgical procedure with a very low mortality rate. It must be 
noted that donors do have to meet the live kidney donor acceptance criteria to reduce 
risk additional to donation. Medical suitability of the donor is assessed by using criteria 
defined by the Amsterdam Forum, a group of experts that developed an international 
standard of care on live donor evaluation in 2004. Despite the excellent results and 
increasing numbers of live kidney donor transplantations, a shortage in donor kidneys 
still remained. Against this background a gradually extension of the donor acceptance 
criteria can be observed in recent years; donors with comorbidities such as cardiovas-
cular disease, obesity and higher age are no longer denied for donation. Until now, 
short-term follow-up studies show excellent results regarding kidney function, morbid-
ity, and mortality. In this thesis, data from the Erasmus MC program for living kidney 
donation, one of the largest programs in this area in Europe with a clear pioneering role, 
are analysed. Focus is directed on evaluation of live kidney donor safety and short-as 
well as long-term results are meticulously evaluated.
Chapter 2 presents a methodological review of the design and analysis of three larger 
studies suggesting a detrimental effect of live kidney donation at long-term follow-up. 
Interestingly, these studies were published by centers that did not observe any nega-
tive effects from live kidney donation in their donor population as described in earlier 
reports. Therefore, we analysed their data and compared reports to uncover contradic-
tory outcomes. The three recent studies reported unfavourable long-term outcomes for 
live kidney donors following donation compared to non-donors, including an increased 
risk for cardiovascular and overall mortality, increased risk for ESRD, and increased risk 
for gestational hypertension and preeclampsia. Previous publications from these same 
research groups did not demonstrated unfavourable outcomes detrimental to live 
kidney donors. Moreover, they reported a lower risk of long-term cardiovascular and 
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overall mortality and lower risk of cardiovascular events. Our detailed review of the 
methodology revealed key differences with respect to selection criteria for donors and 
non-donors, data quality, follow-up, and statistical analysis. Recently published papers 
still face bias. In all studies, the comparison group of non-donors was healthier than 
donors due to more extensive exclusion criteria for non-donors. Selecting a healthier 
comparison group overestimates the risk additional to donation. Furthermore, donors 
could be more aware of their health than non-donors, leading to differential misclas-
sification because all medical conditions could have been registered earlier, thus leading 
to more registered outcomes among donors and an overestimated risk additional to 
donation. Different matching strategies and statistical analyses were used in the more 
recent studies compared to the previous studies. In addition, the follow-up was longer 
in the recent studies. Strong points of the more recent papers as compared to initial 
analyses in the previous studies were the extended follow-up time, large sample sizes 
and better analysis, hence increasing the reliability to estimate potential risks for living 
kidney donors on the long-term. Even if risks are elevated among live kidney donors 
compared to non-donors, the absolute risks for donors following donation are very low 
and should therefore not discourage potential donors.
In 1981, the first live donor kidney transplantation was performed at the Erasmus MC, 
University Medical Center, Rotterdam, the Netherlands. Until now, over 1500 procedures 
have taken place. During this period surgical techniques were improved and evaluated 
by randomized controlled trials, which were conducted between 2001-2004, 2008-2010, 
and 2011-2012. The availability of these large prospective databases gives us the unique 
opportunity to study the long-term outcome. Chapter 3 presents the ten-year follow-up 
of 100 donors included in a previous conducted randomized controlled trial (2001-2004) 
at the Erasmus MC comparing mini-incision open and laparoscopic donor nephrectomy. 
The follow-up period was between November 2011 and February 2014. Ninety-one per-
cent of the initial donor cohort was alive at 10-year follow-up. The donor response rate 
with regard to the quality of life forms was 80%. One donor lives abroad and was lost to 
follow-up. Therefore, annual data on kidney function and blood pressure was available 
for 90% of the donors. Median follow-up of the donor population was 10 years. After 
an initial decline in eGFR in the first year after donation, the kidney function remained 
stable over the rest of the follow-up years, resulting in a median eGFR loss of 14%. Do-
nors with a ten-year eGFR <60 ml/min/1.73m2 had a significantly lower baseline eGFR 
and were significantly older at the moment of donation. No donors were found at risk 
for ESRD. Donors with pre-existing hypertension had a well-regulated blood pressure 
and a median eGFR of 69.0 ml/min/1.73m2 at follow-up. Twenty-three donors developed 
new-onset hypertension 10 years after donation, which was adequately treated with 
medication. These donors had a significantly lower median eGFR at follow-up than 
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donors without hypertension. Donors with new-onset hypertension were significantly 
older at the time of donation than donors who did not developed hypertension. Most 
of the ten-year follow-up quality of life and fatigue scores were significantly decreased 
compared to predonation scores. However, all follow-up data on quality of life and 
fatigue scores was either better or similar as compared to the general population scores. 
Nine donors died during follow-up of unrelated causes to donation.
Chapter 4 presents the five-year follow-up of 190 donors included in a previous con-
ducted randomized controlled trial (2008-2010) at the Erasmus MC comparing left-sided 
laparoscopic and hand-assisted donor nephrectomy. During this period extended donor 
acceptance criteria were already implemented in our center, giving us the unique op-
portunity to evaluate the safety of donors with extended acceptance criteria. Thirty-two 
percent of the donors (n=61) had (multiple) extended eligibility criteria: pre-existent 
hypertension (n=30), age >70 years (n=10), and BMI >30 kg/m2 (n=26). The follow-up 
measurements were between November 2015 and January 2016. Five donors were lost 
to follow-up, leaving clinical data available for >90% of the donors. The mean follow-up 
was 5.1 years. After an initial decline post-donation, the renal function was stable in 
living kidney donors at five-year follow-up; mean eGFR of 60.2 ml/min/1.73m2, with a 
mean serum creatinine level of 105.1 μmol/ml, resulting in a mean decline in eGFR of 
33.7%. Furthermore, no different outcome in eGFR (p=0.479) or eGFR decline (p=0.159) 
was found in donors with extended eligibility criteria (n=61) as compared with donors 
without these criteria. At five-year follow-up none of the donors had proteinuria or mi-
croalbuminuria. The five-year follow-up mean eGFR of male and female donors stratified 
in age categories were significantly different to that of the general population. Ninety-
three donors had an eGFR <60 ml/min/1.73m2 at five-year follow-up without proteinuria 
or microalbuminuria. These donors were significantly older at the time of donation and 
had a significantly lower eGFR pre-donation than donors with a current eGFR of ≥60 ml/
min/1.73m2. In addition, their eGFR decline was significantly higher at five-year follow-
up. No donors were found at risk for ESRD or renal replacement therapy. In longitudinal 
analysis, eGFR and creatinine were significantly affected by male gender and declined 
with ageing. Thirty donors had pre-existent hypertension with a mean eGFR of 57.6 ml/
min/1.73m2 at five-year follow-up with a corresponding mean serum creatinine level of 
103 μmol/ml. Their mean eGFR and serum creatinine level was not significantly differ-
ent than non-hypertensive donors. These donors had well-regulated hypertension at 
follow-up. Twenty-nine donors developed new-onset hypertension, which was mostly 
treated with medication. There was no significant change in mean eGFR and serum 
creatinine level at one-year versus five-year after donation in donors who developed 
new-onset hypertension. The five-year mean eGFR was 54.2 ml/min/1.73m2 with a 
corresponding mean serum creatinine level of 119 μmol/ml. However, their five-year 
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mean eGFR and serum creatinine level were significantly different compared to non-
hypertensive donors, while the eGFR decline was not significantly different. New-onset 
hypertensive donors were significantly older at the time of donation, with a significantly 
higher BMI and a significantly lower eGFR before donation than non-hypertensive do-
nors. Furthermore, there were more new-onset hypertension donors with an eGFR <60 
ml/min/1.73m2 than non-hypertensive donors. Longitudinal analysis demonstrated no 
significant effect of new-onset hypertension on eGFR. All follow-up data from donors on 
quality of life scores were higher as compared to data from the general Dutch popula-
tion, except for the mental component score. Eight donors died during follow-up due to 
causes unrelated to donation.
Live kidney donation is possible due to the capacity of the remnant kidney to compen-
satory increase in size post-donation. It represents renal adaptation and is associated 
with renal function. During live kidney donor screening a CT or MRI is performed to 
assess the size of both kidneys. The correlation between kidney size on these imaging 
modalities and ultrasonography is unknown. As ultrasonography is the preferred imag-
ing modality for follow up after donation, being less time-consuming for health care 
professionals, and less harmful and expensive for patients, we compared the results of 
this imaging technique with CT findings in chapter 5. Fifty consecutive donors, with 
a pre-donation CT-scan, were approached preoperatively for an additional ultrasound 
examination by two ultrasonographists (US-1; US-2). The ultrasound kidney volume 
measurements were compared to the pre-donation CT kidney volume measurement. 
The ultrasound measurements were considered accurate when the mean differences 
between both ultrasonographists for similar measurements were <5 mm. Ultrasound 
volumes were calculated with the ellipsoid equation (length x width x thickness x π/6) 
and an adjusted equation (correction factor 0.674 instead of π/6), and CT volumes with 
the voxel count method. The latter is considered the gold standard. One hundred kid-
neys were measured. The mean differences between US-1 and US-2 for similar measure-
ments of length, width and thickness were <5 mm and were therefore deemed accurate. 
Ultrasound measurements for kidney volume were comparable with the pre-donation 
CT measurements, especially when the adjusted ultrasound volume equation was used. 
Based on these results a personalised correction factor can be calculated.
Chapter 6 presents the preliminary results of a study comparing donors of the Erasmus 
MC donor population from 1981 through 2010 and non-donors from population-based 
cohort studies of the Rotterdam Study and Study of Health in Pomerania (SHIP). Be-
tween 1981 and 2011 a total of 1092 live kidney donations were performed at our center 
and all donors were eligible for inclusion in the analysis; 761 donors were included of 
whom 705 visited the outpatient clinic. Non-donors were included from the Rotterdam 
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Study and SHIP, resulting in 1522 included non-donors; 54.1% from the Rotterdam Study 
and 45.9% from SHIP. Age, baseline systolic blood pressure, ethnicity, and education 
were significantly different between donors and non-donors, but differences were rela-
tively small. The eGFR for the entire studied donor population was a median of 59.9 ml/
min/1.73m2 at follow-up with a median creatinine of 100 μmol/l. The primary outcomes 
for renal function were all significantly inferior for donors compared to non-donors; 
serum creatinine was significantly higher (+26.03 μmol/l (95% CI 24.17; 27.89)) and 
the eGFR significantly lower (-27.23 ml/min/1.73 m2 (95% CI -28.61; -25.85)). The eGFR 
declined 31.70 percent (95% CI 29.94; 33.46) more among donors than non-donors (all 
p<0.001). Sixteen donors (2.4%) and 10 non-donors (1.2%) developed microalbuminuria 
(p=0.09). Two of the included donors (0.3%) developed ESRD. The secondary outcomes 
demonstrated that there is no difference in BMI, new-onset diabetes, and cardiovascular 
mortality between donors and non-donors. A significantly lower risk of developing new-
onset hypertension (OR 0.45, 95% CI 0.33; 0.62) and overall mortality (OR 0.13, 95% CI 
0.06; 0.27) was found among donors. Nine included donors (1.2%) passed away after 
visiting one of the study hospitals prior to their death of non-donation related causes. 
The health-related quality of life score was significantly higher among donors with 0.06 
higher score for EQ-5D  (95% CI 0.05; 0.08 on a scale of -0.59 to 1.00) The SF-12 physical 
and mental component score were both significantly lower among donors: -1.36 (95% 
CI -2.38; -0.33) and -4.61 (95% CI -5.75; -3.47), respectively, on a scale of 0-100. One year 
after donation live donors have a reduced renal function, remaining stable without any 
kidney-related morbidity or mortality to at least eight years of follow-up. However, the 
decline in renal function may be further compromised when unforeseen conditions 
would develop that additionally affect renal function. Having knowledge of this risk, 
albeit small, donors should be well-informed by the medical team and offered lifelong 
follow-up to monitor the remnant renal function.
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Hoofdstuk 1 geeft een overzicht van de ontwikkeling en opkomst van levende nierdo-
natie. De stijgende incidentie van eindstadium nierfalen en het aanhoudende tekort 
aan organen leidde tot nieuwe ontwikkelingen in nierfunctievervangende therapie in 
de jaren ’90. Uit studies bleek dat niertransplantatie de beste prognose biedt met lang-
durig voordeel voor patiënten met eindstadium nierfalen in vergelijking met andere 
nierfunctievervangende therapie. De kloof tussen vraag naar en aanbod van organen 
heeft geleid tot een stijging van het aantal levende nierdonaties in meerdere landen. 
De voordelen van levende nierdonatie ten opzichte van postmortale nierdonatie voor 
de ontvanger werden in meerdere studies aangetoond en betreffen een betere orgaan-
kwaliteit, een verhoogde overleving van het transplantaat en de mogelijkheid om pre-
emptief te transplanteren. Bovendien werden de chirurgische technieken steeds beter 
en studies toonden aan dat het uitnemen van een nier bij een levende donor een veilige 
chirurgischeprocedure is met een zeer laag mortaliteitsrisico. Deze uitkomsten zijn ech-
ter gebaseerd op data uit een periode waarin werd uitgegaan van goed gedefinieerde 
en veilige criteria waaraan een donor moest voldoen om risico’s van de ingreep voor 
de donor zo klein mogelijk te maken. Deze criteria werden in 2004 opgesteld in een 
internationale consensusbijeenkomst georganiseerd in Amsterdam. Ondanks de goede 
resultaten en verdere groei van levende nierdonatie bleef er een tekort aan donornieren 
bestaan. Op basis van enerzijds de goede uitkomsten en anderzijds het persisterende 
tekort aan donornieren werden in de loop der jaren de acceptatiecriteria voor donoren 
geleidelijk verruimd: een minimale comorbiditeit, zoals bijv. hart- en vaatziekten, obesi-
tas en een hogere leeftijd, werd niet meer beschouwd als absolute contra-indicatie. Tot 
op heden tonen studies met een korte termijn follow-up van nierdonoren uitstekende 
resultaten voor nierfunctie, morbiditeit en mortaliteit. In dit proefschrift wordt in dit 
kader de data van het Erasmus MC programma voor nierdonatie bij leven geanalyseerd, 
één van de grootste programma’s op dit gebied in Europa met een duidelijke pioniers-
functie. Zowel korte als lange termijn resultaten zullen worden gepresenteerd met 
nadruk op veiligheid voor de donor.
Hoofdstuk 2 geeft de resultaten weer van een methodologische review naar de opzet 
en analyses van studies van drie gerenommeerde onderzoeksgroepen op het gebied 
van levende nierdonatie. Deze review is opgezet om een verklaring te vinden voor 
de tegenstrijdige resultaten van recente en eerdere studies van dezelfde onderzoeks-
groepen. De meest recente studies tonen ongunstige resultaten voor donoren ten 
opzichte van niet-donoren. Volgens deze studies hebben donoren een verhoogd risico 
op (cardiovasculaire) mortaliteit, eindstadium nierfalen en zwangerschapshypertensie 
en pre-eclampsie. In de drie eerdere studies van deze onderzoeksgroepen was er echter 
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geen sprake van ongunstige resultaten voor donoren. Deze studies lieten juist zien dat 
donoren een lager risico hebben op (cardiovasculaire) mortaliteit en cardiovasculaire 
incidenten ten opzichte van niet-donoren. Onze gedetailleerde beschrijving van de 
methodologie van de zes studies laat belangrijke verschillen zien in de selectiecriteria 
van donoren en niet-donoren, kwaliteit van de data, follow-up duur en statistische 
analyses, die de tegenstrijdige resultaten kunnen verklaren. In de recente studies is 
nog steeds sprake van bias. In alle studies was de vergelijkingsgroep van niet-donoren 
gezonder dan de donoren door de uitgebreidere niet-donor exclusiecriteria. Hierdoor 
worden risico’s die toe te schrijven zijn aan donatie overschat. Daarnaast kan het zo zijn 
dat donoren zich meer bewust zijn van hun gezondheid dan niet-donoren. Dit leidt tot 
differentiële misclassificatie, omdat aandoeningen eerder geregistreerd worden. Hier-
door zijn er meer geregistreerde uitkomstmaten onder donoren, waardoor het risico 
van donatie overschat wordt. Sterke punten van de recentere studies waren de langere 
follow-up duur, de grotere aantallen donoren en de verbeterde statistische analyses. 
Hierdoor zijn de uitkomsten van de recentere studies betrouwbaarder. Ondanks dat 
studies een verhoogd risico onder donoren laten zien in vergelijking met niet-donoren, 
moet benadrukt worden dat de absolute risico’s zeer laag zijn en een toekomstige donor 
niet mogen ontmoedigen.
In 1981 is in het Erasmus MC de eerste nierdonatie bij leven uitgevoerd. Sindsdien zijn 
er meer dan 1500 procedures uitgevoerd. Gedurende deze periode zijn er tussen 2001-
2004, 2008-2010 en 2011-2012 drie gerandomiseerde onderzoeken uitgevoerd om de 
chirurgische techniek te verbeteren. Deze drie grote prospectieve databases bieden 
de unieke kans om langetermijnuitkomsten te onderzoeken. In hoofdstuk 3 worden 
de resultaten gepresenteerd van een 10-jaars follow-up studie onder 100 donoren, die 
tussen 2001-2004 in het Erasmus MC hebben deelgenomen aan een gerandomiseerd 
onderzoek naar mini-open versus laparoscopische donor nefrectomie. De follow-up 
periode eindigde tussen november 2011 en februari 2014, afhankelijk van het moment 
van donatie. Na 10 jaar is 91% van het initiële donor cohort nog in leven. Tachtig pro-
cent van deze donoren heeft de toegestuurde vragenlijsten over de kwaliteit van leven 
ingevuld. Van één donor waren geen follow-up gegevens beschikbaar. Hierdoor was er 
klinische data over de nierfunctie en bloeddruk beschikbaar van 90% van het initiële 
donor cohort. De gemiddelde follow-up was 10 jaar. De nierfunctie is in de loop van de 
afgelopen 10 jaar stabiel gebleven na een initiële daling van de eGFR binnen het eerste 
jaar na de donatie. Dit resulteert in een eGFR verlies van 14% na 10 jaar. Donoren met 
een 10-jaars eGFR <60 ml/min/1.73m2 hadden een significant lagere baseline eGFR en 
waren significant ouder bij de follow-up. Geen van de donoren heeft een risico gehad 
op eindstadium nierfalen. Donoren met een pre-existente hypertensie bleken een goed 
gereguleerde bloeddruk te hebben met een mediane eGFR van 69,0 ml/min/1,73m2 bij 
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follow-up. Drieëntwintig donoren hebben 10 jaar na donatie hypertensie ontwikkeld, 
die adequaat medicamenteus behandeld werd. Deze donoren hebben een significant 
lagere mediane eGFR bij follow-up dan donoren zonder hypertensie. Donoren die hy-
pertensie hebben ontwikkeld, waren significant ouder op het moment van donatie in 
vergelijking met de donoren die geen hypertensie ontwikkelden. De meeste 10-jaars 
scores voor kwaliteit van leven en vermoeidheid zijn significant gedaald ten opzichte 
van de scores ten tijde van donatie. Echter, al deze follow-up scores voor kwaliteit van 
leven en vermoeidheid zijn beter of vergelijkbaar met die van de algemene bevolking. 
Negen donoren zijn gedurende de follow-up overleden aan niet-donatie gerelateerde 
oorzaken.
In hoofdstuk 4 worden de resultaten gepresenteerd van een 5-jaars follow-up studie 
onder 190 donoren, die tussen 2009-2011 in het Erasmus MC hebben deelgenomen aan 
een gerandomiseerd onderzoek naar linkszijdige hand-geassisteerde versus laparosco-
pische donor nefrectomie. Dit cohort is bijzonder omdat in deze periode verruiming van 
acceptatiecriteria voor nierdonoren in ons centrum al was geïntroduceerd. Dit biedt ons 
de mogelijkheid om ook de veiligheid van deze groep donoren te evalueren. Tweeën-
dertig procent van de donoren (n=61) behoorde tot deze groep. De follow-up periode 
was tussen november 2015 en januari 2016. Follow up gegevens waren niet beschikbaar 
voor vijf donoren. Hierdoor was er klinische data beschikbaar van meer dan 90% van het 
initiële donor cohort. De gemiddelde follow-up duur was 5,1 jaar. Vijf jaar na donatie 
is de nierfunctie stabiel gebleven, overigens na een initiële daling van de nierfunctie 
direct na donatie. De 5-jaars eGFR is 60,2 ml/min/1,73 m2 met een gemiddeld serum 
creatinine van 105,1 μmol/ml. Dit resulteert in een eGFR daling van 33,7% na 5 jaar. 
Tevens was er geen verschil in eGFR (p=0.479) en eGFR daling (p=0.159) tussen donoren 
met verruimde acceptatiecriteria en de andere donoren. Bij geen van de donoren was 
er sprake van proteïnurie of microalbuminurie. Na stratificatie van de 5-jaars eGFR van 
mannen en vrouwen in leeftijdscategorieën, blijkt dat de gemiddelden van deze waarde 
significant verschillen van de eGFR waarden van de algemene bevolking. Drieënnegen-
tig donoren hebben een eGFR <60 ml/min/1.73m2 vijf jaar na donatie zonder dat er 
sprake is van proteïnurie of microalbuminurie. Deze donoren waren beduidend ouder 
op het moment van donatie en hadden een significant lagere eGFR pre-donatie dan 
donoren met een huidig eGFR van ≥60 ml/min/1,73m2. Bovendien is de eGFR daling van 
deze donoren significant hoger na vijf jaar follow-up, overigens zonder dat er een risico 
is op nierfalen. Uit de longitudinale analyse blijkt dat de eGFR en creatinine significant 
beïnvloed worden door het mannelijk geslacht en respectievelijk dalen en stijgen met 
de stijging van de leeftijd. Dertig donoren met pre-existente hypertensie hadden na 
vijf jaar een gemiddelde eGFR van 57,6 ml/min/1,73m2 met een serum creatinine van 
103 μmol/ml. De eGFR en het serum creatinine waren niet significant verschillend ten 
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opzichte van donoren zonder hypertensie. De bloeddruk van deze donoren was middels 
medicatie goed gereguleerd bij follow-up. Negenentwintig donoren hebben in de loop 
van 5 jaar hypertensie ontwikkeld, bij de meesten medicamenteus behandeld. Er was 
geen significant verschil tussen de 1-jaars en 5-jaars eGFR of het serum creatinine van 
deze donoren bij een 5-jaars eGFR van 54.2 ml/min/1,73m2 en een serum creatinine van 
119 μmol/ml. Deze waarden zijn wel significant verschillend ten opzichte van de 5-jaars 
eGFR en het serum creatinine van donoren zonder hypertensie. De eGFR daling tussen 
deze twee groepen is niet significant verschillend. Donoren die hypertensie hebben ont-
wikkeld waren significant ouder ten tijde van donatie met een significant hogere BMI en 
een significant lagere eGFR dan donoren zonder hypertensie na 5 jaar. Daarnaast waren 
er meer donoren met een eGFR <60 ml/min/1,73m2 in de groep donoren die hypertensie 
had ontwikkeld dan in de groep donoren die geen hypertensie had ontwikkeld. Uit de 
longitudinale analyse blijkt dat er geen effect is van nieuw ontstane hypertensie op de 
eGFR. Alle 5-jaars kwaliteit van leven scores waren hoger in vergelijking met die van de 
algemene Nederlandse bevolking, met uitzondering van de mentale component score. 
Acht donoren zijn gedurende de follow-up overleden aan niet-donatie gerelateerde 
oorzaken.
Levende nierdonatie is mogelijk, doordat na donatie de overgebleven nier compensatoir 
toeneemt in grootte. Dit is een uiting van adaptatie om te compenseren voor het verlies 
van nierfunctie. Voor donatie wordt de grootte van de nieren bepaald met een CT-scan 
of MRI. Het verschil tussen de grootte van de nier gemeten met voorgaand genoemde 
modaliteiten van afbeeldend onderzoek en echografische bepaling van het niervolume 
zijn onbekend. Echografie is echter de eerste keuze voor beeldvormend onderzoek in de 
follow-up van nierdonoren. Er zijn duidelijke voordelen om echografisch onderzoek te 
gebruiken voor follow-up van nierdonoren: de techniek is niet invasief, het onderzoek 
duurt korter, is patientvriendelijker en brengt minder kosten met zich mee. In hoofdstuk 
5 hebben we uitgezocht of echografisch niervolumemetingen gebruikt kunnen worden 
om de mate van adaptatie en, indirect, de stabilisatie van de nierfunctie na donatie te 
vervolgen. Vijftig opeenvolgende donoren met een predonatie CT-scan werden een dag 
voor de donor nefrectomie benaderd voor een extra echografie onderzoek door twee er-
varen echografisten (US-1 en US-2). De echografie niervolumes werden vergeleken met 
de pre-donatie CT niervolumes. De echografie metingen werden accuraat bevonden als 
het gemiddelde verschil tussen US-1 en US-2 voor dezelfde metingen minder dan 5 mm 
zou zijn. Echografi31,70 niervolumes werden berekend middels de ellips formule (lengte 
x breedte x dikte x π/6) en een aangepaste formule (correctiefactor 0,674 in plaats van 
π/6). De CT volumes werden berekend middels de voxel count methode wat wordt 
gezien als de gouden standaard. In totaal zijn er 100 nieren door de twee echografisten 
afzonderlijk gemeten. De gemiddelde verschillen tussen US-1 en US-2 in lengte, breedte 
Samenvatting 129
8
en dikte metingen is <5 mm en daardoor is aangenomen dat dit accurate metingen 
zijn. Indien de aangepaste niervolume formule wordt gebruikt, komen de echografische 
niervolume metingen overeen met de pre-donatie CT niervolume metingen. Tevens kan 
op basis van deze resultaten een persoonlijke correctiefactor berekend worden.
Hoofdstuk 6 geeft de eerste resultaten weer van een studie waarin donoren van het 
Erasmus MC uit de periode 1981 tot en met 2010 worden vergeleken met niet-donoren 
uit prospectieve cohort studies van de Rotterdam Studie en Study of Health in Pomerania 
(SHIP). In deze periode zijn 1092 levende nierdonaties uitgevoerd in ons centrum, welke 
allen in aanmerking kwamen voor inclusie in deze studie. In totaal zijn 761 donoren geïn-
cludeerd. De gemiddelde follow-up tijd voor donoren was 8,0 (5,1-11,9) jaar. De populatie 
niet-donoren bedroeg 1522 deelnemers, 54,1% van de Rotterdamse Studie en 45,9% van 
SHIP. De gemiddelde follow-up tijd voor niet-donoren was 7,0 (5,4-10,9) jaar. Leeftijd, sys-
tolische bloeddruk, opleidingsniveau en etniciteit toonden een significant verschil tussen 
donoren en niet-donoren, maar deze verschillen waren relatief klein. De gemiddelde eGFR 
voor de geïncludeerde donorpopulatie was 59.9 ml/min/1,73m2 bij follow-up met een ge-
middeld creatinine van 100 μmol/l. De primaire uitkomstmaten voor de nierfunctie waren 
allen significant verschillend voor donoren en niet-donoren (p <0,001). Het serumcreati-
nine was significant hoger met +26,03 μmol/l voor donoren en de eGFR was significant 
lager met -27,23 ml/min/1,73m2. De eGFR daling was 31,70% lager voor donoren. Zestien 
donoren (2,4%) en tien niet-donoren (1,2%) ontwikkelden microalbuminurie (p=0,09). 
Twee van de geïncludeerde donoren (0,3%) ontwikkelden eindstadium nierfalen. De 
secundaire uitkomstmaten tonen dat er geen verschil is in BMI, ontwikkelen van diabetes 
en cardiovasculaire events en sterfte tussen donoren en niet-donoren. Tevens hebben 
donoren een significant lager risico op het ontwikkelen van hypertensie (OR 0,45, 95% 
CI 0,33; 0,62) en sterfte (OR 0,13, 95% CI 0,06; 0,27). Negen donoren (1,2%) overleden na 
inclusie aan niet-donatie gerelateerde oorzaken. De gezondheid gerelateerde kwaliteit 
van leven scores waren lager, maar de verschillen waren relatief klein. In deze studie 
hebben we aangetoond dat donoren een verminderde nierfunctie hebben in vergelijking 
met personen uit de algemene populatie zonder een verhoogd effect op morbiditeit en 
mortaliteit in de geanalyseerde tijdsperiode. Deze studie toont aan dat een jaar na donatie 
levende donoren een verminderde nierfunctie hebben welke daarna stabiel blijft, zonder 
nier gerelateerde morbiditeit of mortaliteit gedurende de geanalyseerde periode. Echter, 
de afname van nierfunctie zou  verder kunnen worden aangetast door onvoorziene medi-
sche omstandigheden die een additioneel effect hebben op de nierfunctie. Met dit risico 
in het achterhoofd, hoe klein ook, dienen donoren goed geïnformeerd te worden door het 
medisch team. Daarnaast is het verantwoord om donoren een levenslange follow-up van 
de overgebleven nierfunctie aan te bieden om deze te kunnen monitoren.
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DANKWOORD
Na vier jaar is het eindelijk zover. het proefschrift is af! Het resultaat van dit proefschrift 
getuigt van een grootschalige team effort. Ik wil iedereen bedanken die heeft bijgedra-
gen aan het tot stand komen van dit proefschrift. Er zijn een aantal mensen die ik in het 
bijzonder wil bedanken.
 
Allereerst wil ik alle 936 donoren bedanken voor de genomen tijd en moeite om deel te 
nemen aan de verscheidene onderzoeken. Zonder uw waardevolle bijdrage aan onze 
onderzoeken zou dit proefschrift er niet zijn geweest.
 
Mijn promotor, prof.dr. J.N.M. IJzermans, beste Jan, binnen de tijd gered! Bedankt dat 
ik het vertrouwen heb gekregen om de nierdonatie onderzoekslijn af te maken. Het 
eindstation is nu echt bereikt. De afgelopen jaren heb ik veel van u mogen leren en 
heb ik de kans gekregen om mezelf op wetenschappelijk gebied verder te ontplooien. 
Onze afspraken werden altijd ingeleid met mooie verhalen, maar gelukkig was er altijd 
nog tijd voor het onderzoek. Bedankt voor alle vrijheid en mogelijkheden die ik heb 
gekregen voor alle activiteiten binnen, maar ook buiten het onderzoek. Ik kan altijd 
rekenen op uw steun.
 
Mijn promotor, prof.dr. A. Hofman, beste Bert, ondanks dat ik geen deel uitmaakte van 
de afdeling Epidemiologie, kon ik altijd bij u terecht voor vragen of een praatje. Zelfs 
de lange afstand doet geen afbreuk aan uw betrokkenheid. Uw enthousiasme voor 
het onderzoek werkt aanstekelijk en ik ben blij dat ik de mogelijkheid heb gehad om 
uw colleges te volgen. Bedankt voor de fijne samenwerking en het gaat u goed aan de 
overkant.
 
Graag wil ik de leescommissie, prof.dr. W. Weimar, prof.dr. E.W. Steyerberg en prof.dr. 
J.J. Homan van der Heide bedanken voor het beoordelen van dit proefschrift en jullie 
waardevolle bijdrage. Tevens wil ik de overige leden bedanken voor de bereidheid om 
als opponent deel te nemen in de grote commissie.
 
Khe, bedankt voor alle kansen die ik van jou heb gekregen. Niet alleen binnen het onder-
zoek, maar ook daarbuiten. Met de Chirurgencup 2015 als het absolute hoogtepunt! 
Met jouw hulp en vastberadenheid krijg je een hoop voor elkaar. Diederik, zonder jou 
was het echoën van al die donoren een onmogelijke opgave geweest. Heel erg bedankt 
voor al jouw hulp en gezelligheid! Frank, jouw toewijding voor onderzoek is oneindig 
en hoe je het allemaal voor elkaar krijgt, is mij een raadsel. Soms duurt het even, maar 
het resultaat mag er altijd wezen. Daarnaast heeft jouw betrokkenheid mij een hoop 
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leerzame en gezellige tripjes opgeleverd. Heel veel succes verder in Londen. Türkan 
en Hermien, bedankt voor al jullie hulp en met name geduld tijdens de robot- en 3D-
laparoscopie studie. Jeroen en Wojtek, bedankt voor het delen van het echo apparaat. 
 
Iedereen van de afdelingen Heelkunde, Nefrologie en Epidemiologie die heeft 
meegewerkt aan de LOVE studie, bedankt. Lieve Mariëlle, mijn steun en toeverlaat 
tijdens deze studie, zonder jouw inzet en geduld was onze inclusie nooit zo hoog gewe-
est. Brigitte, samen met Mariëlle hield je alles op de rails en zouden een hoop gesprek-
ken zijn stil gevallen. Emma, je was de motor achter alle gesprekken, veel succes met de 
overige LOVE projecten. Willij, ik kon altijd op je terugvallen als het nodig was. Patricia 
en Maureen, bedankt voor het luisterende oor op de poli en alle verzamelde buisjes. 
Anneke, zonder jou waren er geen analyses mogelijk. Bedankt voor het bijhouden van 
de database. 
 
Karel, dankzij al jouw voorbereidend werk kon ik zo op een rijdende trein stappen. 
Bedankt voor alles tijdens deze rit.
 
Beste co-auteurs, bedankt voor al jullie input om de manuscripten verder te perfection-
eren. Ine, bedankt voor al jouw tijd en hulp om de donoren in kaart te brengen. 
 
Lieve Carola, jij hebt zoveel betekent voor onze onderzoeksgroep. Ik zou niet weten wat 
ik zonder je had gemoeten. Bedankt voor al jouw hulp en succes met je nieuwe baan. 
Conny, bedankt voor alle gezellige gesprekjes als ik weer eens op wacht stond.  
 
Beste collega-onderzoekers uit de Z-flat, het lab en de Daniël van de afgelopen 4 jaar, 
iedereen bedankt voor alle gezelligheid tijdens de lunches, (m.n. de spontane) borrels, 
(aanloop naar) skireizen, stafdagen (en afterparties in de Blender), huwelijken (incl. 
pitstop en BVO-tjes), bbq’s en sinterklaasfeestjes (met of zonder DVD). Veel succes met 
het afronden van jullie eigen promotieonderzoeken. 
Mijn mede transplantatie-onderzoekers, lieve Jeff, Franny, Renée, Liselotte en Kirsten 
bedankt voor alle gezelligheid tijdens de vele cursussen, congressen en seminars.
Mijn vriendjes en vriendinnetjes van de Epi. Ik kon altijd bij jullie terecht om de leerstof 
weer even op te halen. Veel succes met het afronden van jullie eigen promotieonder-
zoeken.
Lieve collega’s van het Reinier de Graaf Gasthuis, bedankt voor de opvang na jaren in het 
onderzoek te hebben gezeten, de gezelligheid en alle steun in de afgelopen maanden.
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Mijn lieve lil’ studiegenoten (en niet te vergeten jullie plus ones!), bedankt voor alle 
gezelligheid in de collegebanken en vooral ook daarbuiten. Het was een mooie tijd! De 
promotieonderzoeken waren vaak onderwerp van gesprek, maar maken nu plaats voor 
verhalen uit de kliniek, huwelijken (op naar nummer 4 en 5!) en kinderen (waar blijft 
nummer 3?). Op naar nog vele game nights en kerstdiners! 
Mijn paranimf, lieve Linda, we leerden elkaar kennen tijdens de co-schappen en in de 
afgelopen jaren zijn we hele goede vriendinnen geworden. Onze Australië reis was 
fantastisch en had ik met niemand anders willen meemaken. Ik ben ontzettend blij dat 
jij straks aan mijn zijde staat. Ik kan altijd op jou rekenen en jouw plantjes op mij.
Lieve Danish, al meer dan 10 jaar mijn beste maatje door dik en dun, samen altijd op 
één lijn. We zien elkaar nu wel minder, maar zijn altijd op de hoogte en staan altijd voor 
elkaar klaar. Bedankt voor alles de afgelopen jaren.
Lieve familie, we zijn er altijd voor elkaar en ik kan altijd op jullie rekenen. Bedankt voor 
jullie interesse in en betrokkenheid bij mijn promotieonderzoek. We maken er een mooi 
feestje van! 
Mijn lieve broertje, lieve Drawin, we komen uit hetzelfde nest, maar kunnen in sommige 
opzichten niet meer van elkaar verschillen dan dag en nacht. Gelukkig staan we samen 
altijd sterk. De cover is fantastisch geworden! Ik ben zeer trots dat jij straks aan mijn zijde 
staat. 
Mijn lieve ouders, bedankt voor al jullie interesse, steun en vertrouwen. Lieve mam, je 
hebt ons zien opgroeien tot de mensen die we nu zijn. Je bent er altijd voor ons en wij 
zullen er altijd voor jou zijn. Lieve pap, er is niets wat je niet voor ons zou doen. Ik weet 
zeker dat er straks niemand in de zaal zit, die trotser is dan jij. 
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1. PHD TRAINING
Year Workload 
(ECTS)
General courses
- BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’) 2012 1.5
- Systematic literature retrieval 2013 0.5
- Basiscursus in SPSS 2013 0.8
- Centrum voor Patientgebonden Onderzoek 2013 1.0
Specific courses (e.g. Research school, Medical Training)
- Hesperis Course 2013 1.0
- Evidence in Transplantation Course - Systematic review and meta-analysis 2013 0.5
Seminars and workshops
- Erasmus MC Transplant Seminar Series 2013-2016 1.0
- European Transplant Fellow Workshop 2014 2.0
Oral and poster presentations
- European Society of Organ Transplantation Congress 2013, 2015 3.0
- European Association for Endoscopic Surgery Congress 2013, 2016 2.0
- Nederlandse Vereniging voor Endoscopische Chirurgie Jaarcongres 2014 1.0
- World Transplant Congress 2014 2.0
- European Society for Surgical Research Congress 2014 1.0
- Wetenschapsdag Heelkunde, Erasmus MC 2014-2015 2.0
- Nederlandse Transplantatie Vereniging Congres 2014-2015 2.0
- American Transplant Congress 2015-2016 2.0
- International Congress of The Transplantation Society 2016 1.0
(Inter)national conferences
- Chirurgendagen 2013-2016 4.0
- Najaarsvergadering 2014 1.0
- Nederlandse Vereniging voor Endoscopische Chirurgie Jaarcongres 2015 1.0
- Nederlandse Transplantatie Vereniging Congres 2016 1.0
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Lecturing
- Proefstuderen 5/6 VWO scholieren 2013 0.5
- Live Donor Nephrectomy Course 2013-2016 2.0
- 3e Regionale nascholing afdeling Nefrologie, Erasmus MC 2016 0.5
Supervising practicals and excursions, Tutoring
- Examination of Basic Life Support of medical students 2013-2016 1.0
Supervising Master’s theses
- D. Verver 2014 2.0
- E.E.A.P. Mulder 2015 2.0
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Shiromani Janki werd op 25 januari 1986 geboren te ’s-Gravenhage, alwaar zij opgroe-
ide. Na het behalen van haar VWO-diploma aan het Segbroek College te ’s-Gravenhage 
in 2004, startte zij met de opleiding Geneeskunde aan de Erasmus Universiteit Rotter-
dam. De laatste fase van haar opleiding heeft zij voltooid op de afdeling Heelkunde van 
het Reinier de Graaf Gasthuis in Delft, waarna zij 3 maanden doorbracht in Australië 
voor een keuze-coschap op de afdeling Spoedeisende Hulp van het Alfred Hospital in 
Melbourne. In februari 2012 behaalde zij haar artsenbul en een maand later begon zij 
als arts-assistent niet in opleiding op de afdeling Heelkunde van het Erasmus MC in 
Rotterdam. In november 2012 begon zij als arts-onderzoeker aan een promotie-traject 
op de afdeling Heelkunde van het Erasmus MC onder begeleiding van prof.dr. J.N.M. 
IJzermans (Heelkunde) en prof.dr. A. Hofman (Epidemiologie). De onderzoeken naar 
langetermijngevolgen na nierdonatie hebben geleid tot de totstandkoming van dit pro-
efschrift. Tijdens haar promotie-traject heeft zij de Master of Health Sciences opleiding 
afgerond met als specialisatie Clinical Epidemiology aan het Netherlands Institute for 
Health Sciences - Erasmus MC. Na afronding van haar promotie-traject in juli 2016 is zij 
weer teruggekeerd naar de kliniek als arts-assistent niet in opleiding.
